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AVIAN INFLUENZA A VIRUS TRANSMISSION AND THE EMERGENCE OF 
DRUG RESISTANCE 
As avian influenza A viruses (AIV) continue to circulate worldwide both 
naturally, within the reservoir host of wild waterfowl, and cross species barriers, 
eventually establishing itself in new host species, it is imperative to study the natural 
reservoir in respect to virus change and transmissibility.  This dissertation will focus on 
the transmissibility of a mallard virus from mallards to other wild and domestic species as 
well as elucidate the possible outcomes of oseltamivir contamination in the environment 
and its effect on influenza A virus infected mallards. 
Low pathogenicity (LP) AIVs of the H5N2 and H7N3 subtypes were utilized to 
evaluate the ability of transmission of a mallard derived virus to other species present in a 
co-habitation (barnyard) scenario.  Other species in contact with the mallards were 
chickens, blackbirds, rats, and pigeons.  Viral replication was assessed directly from 
ducks in the barnyard with assessment of the other animals in the barnyard through sero-
conversion.  Additional animals of each species were directly inoculated with these two 
viruses and assessed for viral replication. The H5N2 virus was transmitted to other ducks 
and chickens in the barnyard through either direct or environmental contamination, but 
not to rats or blackbirds. The H7N3 virus was transmitted to other ducks, chickens, 
pigeons, and rats. 
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Chickens and blackbirds directly inoculated with both virus strains shed 
significant amount of virus and seroconverted, but rats and pigeons (except for one 
pigeon) failed to shed virus but did develop antiviral antibodies.  Knowing that both 
mallard viruses can directly transmit without adaptation, show the mallard to be a good 
model to further evaluate the outcome of oseltamivir contamination in the environment 
and its effect on AIV infected mallards. 
The environment has been shown to be contaminated with significant amounts of 
oseltamivir carboxylate (OC) in an area of high drug prescription use.  We analyzed the 
outcomes of AIV in infected mallards when they have access to OC in their drinking 
water.  Two separate LPAIV H5N2 viruses were tested for their ability to mutate under 
drug pressure.  One H5N2 virus did not demonstrate any altered sequence after 7-10 days 
of drug access and infection.  The other H5N2 virus did show mutations in the 
neuraminidase gene that led to an increase in resistance to oseltamivir caused by a 
specific mutation at E119V.  This resistant virus was further evaluated for its ability to 
transmit between infected and naïve mallards.  While the resistant virus did transmit duck 
to duck, the mutation at position 119 was not detected after challenge or transmission 
showing instability of this mutation.  This could either be a reversion to wild-type or 
possibly the low level presence of wild-type present in the resistant strain stock that 
outcompeted with the mutant strain to succeed in the host.  This shows, that in these duck 
experiments, the E119V mutation is not stable in the absence of drug pressure and 
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CHAPTER 1: REVIEW OF LITERATURE 
Overview 
Avian influenza has been known as a disease of birds since the late 1800‟s and the 
virus has continued evolving and adapting throughout the world to the present day.  
Avian influenza has not only affected the wild avian population and domestic avian 
species but has adapted to infect humans, pigs, horses, cats, dogs, sea mammals, and 
other land mammals, with certain strains establishing themselves in these new hosts.  
Since 1918, there have been five major influenza pandemics affecting humans, with the 
most recent in 2009 that left us with many more questions than answers in how to battle 
this disease.  The recent outbreak of highly pathogenic H5N1 virus that was first seen in 
humans in 1997, with a resurgence in 2003, stimulated the scientific community to 
develop many vaccines to combat constantly evolving virus strains and to evaluate 
numerous antiviral medications.  Creating a new vaccine at the start of a pandemic would 
take up to 6 months, thus management of the outbreak will require the use of antiviral 
drugs.  Several anti-influenza antivirals have been evaluated for protection from highly 
pathogenic strains of avian influenza virus, but only a select few have been approved and 
stockpiled for use.  In humans, the increase in drug resistant strains in response to the 
most commonly stockpiled drug is concerning, as is the predicted environmental buildup 
of these drugs if used worldwide in mass quantities.  These concerns strongly argue for 




Classification of Influenza Viruses 
Influenza viruses are members of the Orthomyxoviridae family and classified into 
five genera: influenza A, influenza B, influenza C, Thogotovirus, and Isavirus (Kawaoka 
et al, 2005).  All influenza viruses contain a segmented, linear, negative sense, single 
stranded RNA genome.  The number of segments differs with influenza A and B viruses 
and Isavirus containing 8 segments (McGeoch et al, 1976, Palese & Schulman, 1976a, b, 
Palese et al, 1980, Mjaaland et al, 1997), influenza C virus having 7 segments (Palese et 
al, 1980), and Thogotovirus containing 6 segments (Clerx et al, 1983).  This review will 
focus on influenza A viruses, and its 8 segment encoding properties are summarized in 
Table 1.1. 
Table 1.1. Influenza A virus genome 
Segment Length (nt) Encoded 
polypeptide 
Protein name 
1 2341 PB2 Polymerase basic 2 
2 2341 PB1 Polymerase basic 1 
  PB1-F2  
3 2233 PA Polymerase acidic 
4 1778 HA Hemagglutinin 
5 1565 NP Nucleoprotein 
6 1413 NA Neuraminidase 
7 1027 M1 Matrix 1 
  M2 Matrix 2 
8 890 NS1 Nonstructural 1 
  NS2 Nonstructural 2 
 
 
Structure of Influenza A Viruses 
 Influenza virus particles are considered pleomorphic and can appear spherical or 
filamentous in appearance (Bourmakina & Garcia-Sastre, 2003, Chu et al, 1949).  All 
influenza viruses contain a protein and RNA core that is surrounded by a lipid layer, or 
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envelope.  There are three viral integral membrane proteins, with two that extend 
externally from the lipid layer:  the hemagglutinin (HA) and neuraminidase (NA).  The 
HA protein resembles a spike shaped trimer extending outward from the lipid layer and is 
the most abundant viral surface protein (Compans et al, 1970).  The HA protein has two 
major functions.  First, it binds to sialic acid receptors on the host cell via the receptor 
binding site in a pocket located on each subunit, leading to the attachment of virus to the 
host cell.  Second, the HA protein is required for fusion of the virus with the host cell 
membrane and penetration of the virus into the cell cytoplasm, which is triggered by low  
pH and conformational change of the HA protein leading to fusion of viral and endocytic 
membranes leading to the release of RNPs into the host cell. As described below, 
antigenic changes in the HA endow influenza viruses with a potent ability to evade host 
immunity.  
 The NA protein is a spike-shaped tetramer extending from the lipid layer, and is 
integral in both viral attachment and viral release from the host cell.  The complete virion 
is released from the cell membrane by the enzymatic activity of NA which cleaves the α-
ketosidic linkage between the terminal sialic acid and it‟s adjacent sugar residue to which 
the HA is bound (Gottschalk 1957).  The cleavage of sialic acid leads NA to play a role 
in both viral attachment (Matrosovich et al, 2004) viral release, and viral spread by 
removing nearby sialic acid receptors from carbohydrates on the viral glycoprotein, 
thereby preventing aggregation of viral progeny (Palese et al, 1974, Palese and Compans 
1976). This activity requires a delicate balance between HA and NA so that viral particles 
do not aggregate at the cell membrane and so released progeny can continue the cycle 
and infect other cells (Kaverin et al, 1998, Mitnaul et al, 2000, Wagner et al, 2002).   NA, 
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like HA also plays a major role as an antigenic determinant that undergoes antigenic 
variation. 
 The third integral membrane protein is the matrix 2 (M2) protein that extends the 
entirety of the lipid layer and projects from the surface of the virion. The ectodomain of 
the M2 protein (M2e) that extends from the surface of the virion has become attractive as 
a vaccine prospect due to the high sequence conservation of this region across influenza 
A viruses in humans as well as sequence conservation between human and avian strains 
(Lamb et al, 1985).  The M2 protein functions as a proton channel (Pinto et al, 1992) and 
is necessary for triggering viral uncoating.  M2 has also been targeted by antivirals as a 
way to inhibit viral replication and is discussed in more detail below.  
 The matrix 1 (M1) protein lies beneath the lipid envelope in a layer extending the 
circumference of the virion and interacts with ribonucleoproteins (RNPs), forming a 
bridge between inner core components and membrane proteins, and allowing assembly of 
viral products and budding of the virion from the host cell (Gomez-Puertas et al, 2000, 
Latham & Galarza 2001).  M1 not only promotes binding to RNA but it also acts as a 
nuclear localization signal (NLS) based on a specific signal sequence at amino acids 101-
105 to promote transport from the cytoplasm to the nucleus (Elster et al, 1997, Ye et al, 
1995). 
 The remaining proteins are all internal and involved with RNA replication and 
transcription.  These are the nucleocapsid protein (NP) which coats the RNA, and the 
complex of three proteins which constitute the RNA dependent RNA polymerase.  NP is 
a major structural protein that encapsidates viral RNA.  NP protein is involved in RNA 
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synthesis and RNA nuclear export, and is required for the import of viral RNA (Cros et 
al, 2005, O‟Neil et al, 1995). 
 The influenza virus RNA dependent RNA polymerase is a heterotrimer composed 
of three subunits designed polymerase basic 1 (PB1), polymerase basic 2 (PB2) and 
polymerase acidic (PA), so named based on their basic or acidic amino acid composition.   
PB1 displays catalytic activity, nucleotide polymerization, and chain elongation (Braam 
et al, 1983). PB1 possesses four conserved motifs that recognize it as a RNA-dependent 
RNA polymerase, and show the critical role of PB1 in RNA-transcription replication 
(Biswas & Nayak 1994). The PB1 gene also encodes a second protein PB1-F2 which 
regulates influenza A virus-mediated apoptosis by targeting the mitochondria, causing 
destabilization of the mitochondrial membrane with some H1N1 strains, but not in H5N1 
strains possibly due to its cellular localization; it contributes to viral RNP activity and 
aids in viral RNA replication (Chen et al, 2001, Chen et al, 2010).   PB2 binds to the 5' 
cap of host messenger RNA molecules, after which PB1 cleaves the cap for incorporation 
into viral RNAs (so called “cap snatching”). While most PB2 protein localizes in the 
nucleus, PB2 also localizes to the mitochondria and interacts with IPS-1, a mitochondrial 
antiviral signaling protein, but also shows differences in strain specificity like PB1, with 
seasonal strains targeting the mitochondria but nonmitochondrial targets in H5N1 viral 
strains (Graef et al, 2010).  This strain-specific amino acid polymorphism in H5N1 
strains leads to induction of higher levels of IFN-β, leading to attenuation in the animal 
model when there is overexpression of PB2, whereas the PB2 protein that targets 
mitochondria inhibits the production of INF-β (Graef et al, 2010).  PA is the third 
component of RNA polymerase that interacts with PB1 and has protease activity (Sanz-
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Ezquerro et al, 1995) with other functions still being investigated.  Recent elucidation of 
the PA protein includes a more detailed understanding of its role, not only with protease 
degredation of both viral and host proteins but endonucleotic cleavage of capped RNA 
primers and transcript elongation (Fodor et al, 2002, Fodor et al, 2003).  Like PB1-F2 and 
PB2, PA also has some involvement with mitochondrial proteins and regulation of 
apoptosis (Bradel-Tretheway et al, 2011). 
 The final set of proteins encoded by the genome of influenza A virus are the non-
structural proteins. Originally they were given this designation because they had not been 
found to be present in virions but it has been discovered that NS2 has been isolated from 
purified virus (Richardson & Akkina, 1991).  The nonstructural protein 1 (NS1) is 
considered multi-functional and works as a viral interferon antagonist by suppressing the 
host's immune response induced by the viral infection.  Studies with NS1 mutants have 
determined that if NS-1 is not present, it increases the pathogenicity in vivo in animals 
lacking both STAT1 (Garcia-Sastre et al, 1998) or dsRNA-activated protein kinase, PKR 
(Bergmann et al, 2000, Kochs et al, 2007), both of which are antiviral mediators.  NS1 
can be divided in two parts, the RNA-binding domain (Chien et al, 2004, Hatada & 
Fukuda 1992, Qian et al, 1995) and the C-terminal effector domain, which mediates both 
the interactions with host cell proteins and functionally stabilizes the RNA-binding 
domain (Wang et al, 2002).  Nonstructural protein 2 (NS2) which is also called the 
nuclear export protein is involved in nuclear export of viral RNPs (O‟Neill et al, 1998).  
NS2 binds to M1 through ionic interactions in the C-terminal domain and is responsible 
for both the nuclear export of viral RNPs and for blocking re-entry of vRNPs into the 
nucleus by blocking the action of NLS of the M1 protein (Shimizu et al, 2011).  NS2 also 
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has a nuclear export signal that interacts with the protein CRM1 which plays a role in 
trafficking. 
Replication of influenza A viruses 
 Replication of influenza A virus is initiated through binding of the viral HA 
protein to the host cell via a specific sialic acid (SA) bound to a galactose.  SA molecules 
are named based on both their chemical composition (N-acetylneuraminic acid or N-
glycolneuraminic acid) and the sugar linkages to the α-2 carbon, and are designated as 
α2-3 or α2-6.  There is diversity in the affinity of different HA proteins for the two SA 
structures.  In general, avian influenza viruses prefer SAα2-3 linkages, with NeuSA-α-
2,3-gal being present in duck intestinal cells (Ito et al, 1997, 2000), while human 
influenza viruses bind preferentially to SA with α2-6 linkages (Rogers & Paulson, 1983, 
Baum & Paulson, 1990, Conner et al, 1994).  Cells of the upper respiratory tract of 
humans contain predominantly SA-α-2,6-gal (Baum & Paulson, 1990), but SA-α-2,3-gal 
is present on ciliated cells in the lower respiratory tract (Matrosovich et al, 1999, 2004, 
van Riel et al, 2006, Shinya et al, 2006).  The differing affinities of HA molecules for 
different SA receptors is an important determinant of host range.  For example, most 
mammals are relatively poor hosts for avian influenza viruses, as will be discussed in 
detail later. 
 Once the virus has bound, the virion is endocytosed into the host cell.  During the 
endocytosis process, the M2 protein allows for the influx of protons leading to an acidic 
environment (Matlin et al, 1981).  This low pH leads to a conformational change in the 
HA, which in turn triggers fusion of the viral and endocytic membranes and dissociation 
of M1 from the RNP complex (Matlin et al, 1981, Zhirnov et al, 1994).  Once the two 
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vesicles are fused, the M1 protein promotes the expulsion of the RNP from the vesicle 
and its transport to the nucleus of the host cell (Martin et al, 1991). PB1 and PA have 
been shown to accumulate both in the cytoplasm and the nucleus, but do not accumulate 
in the nucleus without forming a dimer with each other before nuclear entry.   PB2 enters 
the nucleus independently, then in that compartment forms a trimer with PA and PB1 
(Fodor & Smith, 2004).  The interaction with viral genomic RNA (vRNA) appears to 
occur with the PA/PB1 dimer before joining with PB2 (Deng et al, 2005).  Transport into 
the nucleus is aided by karyopherin α and karyopherin β that bind to the complex of NP 
protein and vRNA.  Karyopherin α recognizes a NLS-containing cargo protein on NP, 
which recruits karyopherin β which binds to the nucleus at the nuclear pore (Cros et al, 
2003).  
 Once inside the nucleus, the polymerase complex composed of PA, PB1, and PB2 
initiates primary transcription of mRNAs from vRNA, beginning with the phenomenon 
of cap snatching.  This involves the stealing of a 5′ capped primer from host pre-mRNA 
transcripts (Krug 1981).  Transcription in then initiated when the 5′ end of vRNA binds to 
the PB1 subunit, which allows PB2 to recognize and bind to the pre-mRNA (Cianci et al, 
1995, Fechter et al, 2005, Li et al, 1998).  This change in polymerase leads to an 
increased affinity of PB1 for the 3′ end of the vRNA forming a duplex (Lee et al, 2003).  
The PB1 then exerts its endonuclease activity, cleaving pre-mRNAs initiating 
transcription and chain elongation.  The synthesis of viral mRNA is completed with the 
polyadenylation on the 3′ terminus of the newly synthesized RNA.  The vRNA segments 
also serve as templates for the production of cRNA but without the need for a capped 
primer; in this case, an exact copy of viral genomic RNA is produced.  Once the positive 
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sense cRNA is produced, it serves as the template for the production of additional copies 
of negative sense vRNA.  Once viral replication has occurred, the RNP complexes are 
transported out of the nucleus with the aid of M1, NEP/NS2 and an export receptor 
CRM1 (Neumann et al, 2000).  CRM1 binds to the target protein that contains a leucine 
rich NES (Fornerod et al, 1997, Fukuda et al, 1991, Ossareh-Nazari et al, 1997) which 
M1 does not possess, but NS2 does, leading to a complex of NS2-M1-vRNP-CRM1 
which exports the complex out of the nucleus into the cytoplasm.  Once in the cytoplasm, 
the vRNP-M1-NS2 can be incorporated into the virion and assembly at the plasma 
membrane occurs with M1 playing a dual role in both trafficking and assembly.  HA, NA 
and M2 proteins are processed in the endoplasmic reticulum into their appropriate 
configurations, then transported to the Golgi apparatus where cysteine residues of the HA 
and M2 proteins are palmitoylated (Steinhauer et al, 1991, Sugrue et al, 1990, Veit et al, 
1991,1991,1993).  These modified proteins are then transported to the plasma membrane 
to finish assembly of all eight viral segments into a complete viral particle before the 
budding process is initiated.  The virion is released from the cell surface through the 
action of NA cleaving the appropriate sialic acid.  Early studies were done with a 
transition state neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic 
acid (FANA), which works to mimic the enzymatic substrate of NA and blocks viral 
release leading to inhibition of viral replication (Kilbourne et al, 1974, Palese et al, 1974, 
1976).  This valuable concept elucidating a major function of NA led to the later 
development of neuraminidase inhibitors in use today which utilize the same mechanism. 
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Evolution of influenza A viruses 
Influenza viruses have the ability to infect and cause disease in a very broad range 
of avian and mammalian species due to the plasticity of their genome.  Genomic diversity 
is acquired through two fundamental mechanisms: an intrinsically high rate of mutations 
and the ability of the virus to reassort gene segments.  RNA viruses in general have high 
rates of mutation due to their lack of an exonuclease activity and inability to edit 
misincorporated nucleotides during RNA replication (Steinhauer et al, 1992).  This high 
error rate leads to a quasispecies scenario, with many different genotypes generated that 
have the ability to succeed within the host depending on the level of fitness of the 
different viruses (Domingo et al, 1985).  This is advantageous for the virus in allowing it 
to better evade the host‟s immune response and rapidly adapt to the new host (Manrubia 
et al, 2005).  The low fidelity of RNA replication can also be a disadvantage in that many 
of the different genotypes produced will not be productive and will be eliminated from 
the host.   
Changes in viral genomic sequence caused by many mutations over time, is 
referred to as antigenic drift.  Protection is afforded in the host from antibodies generated 
by the immune response to viral infection, which in theory would provide protection 
against the HA of the same subtype but not between subtypes.   Over time, it became 
clear that vaccines made for a specific subtype did not necessarily protect even against 
viruses of the same subtype due to alterations in the structure of antigenic sites.  The 
changes in amino acid sequence over time are more likely in the HA and NA genes 
(Nobusawa et al, 1991).  A consequence of antigenic drift of huge importance to public 
health is evident from the formulation of human seasonal influenza vaccines, which have 
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to be updated yearly due to best match the most common circulating strains of virus 
(Smith 2003).  For the human influenza A H3  protein, there are five specific antibody-
binding regions located on the globular head of the HA protein near the receptor binding 
site that are considered protective to the host (Webster & Laver, 1980, Wiley et al, 1981, 
Wilson et al, 1981).  These regions accumulate amino acid changes that over time can 
alter a specific neutralizing epitope that prevents the antibody from binding (Webster & 
Laver, 1980).  This allows the virus to escape the host immune response, thus 
perpetuating viral replication and transmission. 
The ability of influenza virus gene segments to reassort is called antigenic shift.  
Antigenic shift is described as the introduction of an antigenically distinct virus within a 
population that is different from currently circulating strains, and to which the population 
has no immunity.  This lack of immunity allows the virus to spread rapidly within a 
population, sometimes leading to a pandemic.  Important examples of known human 
influenza pandemics due to antigenic shift are the H1N1 subtype in 1918, H2N2 in 1957, 
H3N2 in 1968, H1N1 reappearance in 1977 and most recently, the H1N1-swine origin 
virus from 2009.  Pandemics are determined by the presence of three factors: 1) a novel 
virus must be present in the population, 2) the virus must have the ability to cause illness 
in the host, 3) there must be sustained human to human transmission.  These events can 
occur by either the sudden introduction in the human population from an animal 
population, or a reassortment event between circulating strains of avian influenza and 
host-adapted human or swine influenza viruses (Wright et al, 2007, Dawood et al, 2009).  
Both the 1957 and 1968 strains are human and avian reassortants (Wright et al, 2007). 
The 1918 H1N1 virus was new to the human population, and introduced directly from an 
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avian source, either through adaptation of an avian H1N1 or a human-avian reassortment 
event (Reid & Taubenberger 2003, Reid et al, 2004).  It has also been suggested that this 
virus was transmitted from humans to swine during the same time period when swine 
epizootics were occurring (Chun 1919, Koen 1919).  Retrospective sequencing of the 
1918 human H1N1 virus and swine viruses which were first isolated in the 1931 (Shope 
1931) suggest that the H1N1 strain circulating in 1918 mixed between humans and swine 
and separated into two separate lineages; human-H1N1, which was isolated up until 1957 
with a possible laboratory exposure causing the human H1N1 lineage to re-appear in 
1977 (Nakajima et al, 1990, Taubenberger et al, 2007), or swine-H1N1 strains that are 
still circulating today (Kanegae et al, 1994).  The most recent H1N1 pandemic resulted 
from generation of a reassortant virus with genes previously seen in a human-swine-avian 
triple reassortant present in North America with genes circulating in Eurasian swine 
(Dawood et al, 2009).  H1N1 influenza virus first appeared in European swine in 1979 
(Easterday & Van Reeth 1999) with H3N2 appearing in European swine in the mid 1980s 
and mid 1990s in the United States.  Both H1N1 and H3N2 viruses still circulate 
worldwide in swine (Swayne 2008).   
Influenza A virus has also established itself in horses; first with the H7N7 
subtype, in the 1950‟s followed by a H3N8 subtype virus.  It is this equine H3N8 
influenza A virus that was transmitted to dogs and has since established itself widely in 
the canine population (Castleman et al, 2006, Crawford et al, 2005, Payungporn et al, 
2008). More recently in South Korea, an avian influenza A H3N2 virus was  detected in 
dogs (Song et al, 2008), suggesting direct interspecies transmission from birds to dogs. 
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The knowledge that waterfowl are the primary reservoir of influenza virus allows 
a complete study of evolution of the virus in this species. The conclusion that influenza is 
evolving at a much slower rate in wild avian species, and the consensus of conservation 
of sequence from many different avian sources, show adequate adaptation to the avian 
host and a continued perpetuation of the virus within wild avian species confirming their 
reservoir status (Suarez 2000).  This is made possible in part due to the low pathogenic 
nature of influenza in wild ducks that allows for limited disease but high rates of 
shedding that lead to transmission within duck populations and ultimately to other 
susceptible hosts (Webster et al, 1978, Kida et al, 1980, Cooley et al, 1989).  
Epidemiology of Avian Influenza A viruses 
Avian influenza virus was first isolated from a common tern (Sterna hirundo) in 
South Africa in 1961, A/tern/South Africa/61 (H5N3), and was the first highly 
pathogenic avian influenza virus (HPAIV) isolate to be recovered from wild birds 
(Becker 1966).  Viruses were subsequently isolated from wedge-tailed shearwaters 
(Puffinus pacificus) in Austrailia (Downie & Laver, 1973) and from wild ducks in 
California (Slemons et al, 1974).  Since then, it has been determined that all known HA 
(H1-H16) and all known NA (N1-N9) subtypes are found in waterfowl (Hinshaw et al, 
1980, Hinshaw et al, 1982, Suss et al 1994, Olsen et al, 2006).  The waterfowl that harbor 
influenza A viruses can be divided into two separate orders, the Anseriformes, which 
include ducks, geese and swans, and the Charadriiformes, which include gulls, terns and 
shorebirds, both groups of which are distributed globally.  While wild birds are generally 
accepted as the natural reservoir of all influenza viruses, wild ducks throughout North 
America and Northern Europe have a more limited range of carrying H1-H12, H14 and 
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N1-N9, while H13, H15 and H16 appear to be relegated primarily to shorebirds (Sharp et 
al, 1993, Hanson et al, 2000, Krauss et al, 2004, Olsen et al, 2006). While all subtypes 
appear in waterfowl, there appears to be a more limited subset of viruses for which wild 
ducks are the reservoir.  Studies conducted in North America and Europe have shown 
that there are dominant subtypes in wild ducks that are isolated from both adults and 
juveniles and are of the HA subtypes H3, H4, and H6, along with NA subtypes N2, N6, 
and N8 (Sharp et al, 1993, Krauss et al, 2004, Munster et al, 2005, Hanson et al, 2003); 
H9 and H13 subtypes predominate in shorebirds (Kawaoka et al, 1988).  Prevalence of 
AIV in ducks peaks during late summer and early fall and to higher numbers in juveniles 
due to increased numbers in pre-migration areas and possibly due to lack of immunity in 
juveniles (Hinshaw et al, 1985, Krauss et al, 2004, Wallensten et al, 2007).  The rates of 
virus isolation decrease as birds migrate south (Stallknecht et al 1988, Krauss et al, 
2004).  Host age has also been shown to play a role in the quantity of virus shed from 
mallards, with birds 1 month of age shedding the most virus and on more collection time 
points than virus isolated from mallards tested at 2 weeks, 2 months, 3 months, and 4 
months of age (Costa et al, 2010).  Pathogenicity of AIV in mallards has also been 
reported to differ based on age (Pantin-Jackwood et al, 2007), suggesting that the age at 
which infection occurs could play an important role in the ultimate transmission of the 
virus. Long term studies in wild ducks have shown a clear periodicity in 2 year intervals 
for isolation rates with approximately 1 to 2 years between highs and lows (Hinshaw et 
al, 1985, Krauss et al, 2004). 
Since AI viruses in wild ducks are primarily transmitted by the fecal/oral route, 
one must consider both the environment as well as shedding capacity of the duck.  The 
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longer AIVs are shed from the host and persist in the environment, the higher the 
probability of transmission among ducks and other species.  Webster and colleagues 
(1978) first demonstrated that experimentally infected ducks shed large quantities of 
virus, and others have shown that virus shedding can be detected from ducks for more 
than 28 days (Hinshaw et al, 1980).  AIV has also been isolated from natural water 
sources, providing another source of infection (Hinshaw et al, 1980, Halvorson et al, 
1983, Ito et al, 1995), and models have been constructed to better understand the 
potential role of contaminated water in yearly cycles infections (Roche et al, 2009).  
Several in vitro studies have also evaluated different strains of AIV to determine the 
environmental persistence of AIV in water and to evaluate the effects of temperature, pH 
and salinity on persistence (Webster et al, 1978, Brown et al, 2006, Stallknecht et al, 
1990a and b, Negovetich & Webster, 2010, Achenbach & Bowen, 2011). 
 Mallards (Anas platyrhynchos) are the most commonly studied species of the 
Anseriformes and are infected with influenza virus more often than other birds (Olsen et 
al, 2006).   Short term infection studies using mallards have shown some level of 
heterosubtypic and homosubtypic immunity does exist.  This causes minimal illness on 
the mallards and allows their interactions with other birds and migration to be unhindered 
(Kida et al, 1980, Fereidouni et al, 2009, Jourdain et al, 2010).   However, this transient 
immunity also decreases shedding, which may impact the ability to transmit (Latorre-
Margalef et al, 2009).  The concern remains that mallards continue to transmit AIV while 
undertaking long distance migration, leading to perpetuation and spread of the virus, 
particularly at stopover sites (Olsen et al, 2006, Wallensten et al, 2007).   
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 Generally, it is wild birds that introduce LPAIVs to domesticated birds such as 
chickens, turkeys, quail and other game birds.  These transmission events occur either 
through direct contact or contact with contaminated surfaces and water.  Once the virus 
has established itself in domesticated birds through adaptation, the potential to spread to 
mammals is increased.  This has led to the recent concerns with H5N1 HPAIV viruses.  
 An influenza virus considered to be a major concern to public health is highly 
pathogenic H5N1.  This pathogen was first detected in 1997 in Hong Kong (Claas et al, 
1998, Subbarao et al, 1998) and has continued to spread west through Asia, Europe, the 
Middle East, and Africa. The rapid evolution of H5N1 HPAIV, through both antigenic 
shift and antigenic drift, has generated 10 distinct clades (clades 0-9) (Donis et al, 2008).  
Initial fears of a pandemic centered on domestic poultry that had been in contact with 
humans, and there was little concern that this virus was spread from migratory species.  
Eventually, it was discovered that wild birds were also succumbing to infection from 
H5N1 HPAIV (Olsen et a, 2006, Liu et al, 2005, Ellis et al, 2004, Chen et al, 2005). 
 Early reports indicated that HP H5N1 viruses were non-pathogenic in mallards 
(Brown et al, 2006, Keawcharoen et al, 2008) or had the ability to become non-
pathogenic through evolutionary adaptation in the duck host while remaining highly 
pathogenic to domestic poultry.  Such a case would allow for the possibility that 
migrating ducks could transmit the HP virus to poultry without themselves suffering 
disease (Hulse-Post et al, 2005).  A recent H5N2 HP virus was isolated in Nigeria from 
two healthy wild waterfowl (Gaidet et al, 2010), validating continued concern that wild 
birds with subclinical infection can be a significant source of virus to the poultry they 
contact.  On the other hand, some recent H5N1 strains are clearly highly pathogenic to 
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wild ducks and other waterfowl, vividly demonstrating diversification of H5N1 strains 
and leading to concerns for the future evolution of these strains and their effects on 
humans.  H5N1 AIV continues to be detected in wild birds and is endemic in domestic 
ducks and poultry in several regions of the world.  This virus should continue to be 
viewed as a major threat to animal and human health.  
Pathogenesis of avian influenza A virus infection  
 The ability of influenza A viruses to induce disease varies greatly among host 
species and even within the same subtype.  For example, infection of humans with many 
H1N1 viruses induces a mild disease (seasonal influenza), whereas other H1N1 viruses 
have killed millions of people (e.g. the Spanish influenza epidemic of 1918).  Analysis of 
the reconstructed 1918 influenza virus indicated that all original 8 gene segments together 
were required to recreate the virulence of the virus as a whole; replacing just one gene at 
a time greatly reduced virulence (Tumpey et al, 2005).  Another excellent example of 
differing virulence among viruses of the same subtype is observed with avian influenza A 
viruses, which can be classified as HPAIV or LPAIV based on the responses of domestic 
chickens to infection.  These differences in virulence appear to result from a complex 
interaction of several viral proteins acting in concert.  
The HA gene and its encoded protein play an important role in virulence and 
pathogenicity.  While the terms pathogenicity and virulence have been used 
interchangeably they are distinct from one another.  Pathogenicity refers to the ability of 
the virus to infect and cause disease in a susceptible host and spread from host to host.  
Pathogenicity also involves the genetic component of the virus where the damage 
incurred on the host is due to host-virus interactions.  Virulence refers to the degree of 
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damage caused by the virus which correlates with the ability of the virus to replicate in 
the host.  Before the HA gene becomes fully functional it must be cleaved by a host 
protease that divides it into two separate subunits, HA-1 and HA-2 leaving the fusion 
peptide on the HA-2 region exposed.  The cleavage and release of the fusion peptide is 
necessary for the initiation of a productive infection to occur (Klenk et al, 1975, 
Lazarowitz & Choppin 1975).  To date, the only avian HA genes and proteins associated 
with a highly pathogenic phenotype are H5 and H7.  The necessary molecular change 
from LP to HP generally occurs when the virus moves from its natural reservoir to 
poultry species (Webster, 1998).  In multiple cases, a closely related progenitor LPAIV 
has been detected circulating immediately prior to an outbreak involving the 
corresponding HPAIV (Kawaoka et al, 1984, Horimoto et al, 1995, Garcia et al, 1996, 
Suarez et al, 2004, Bowes et al, 2004, Hirst et al, 2004).   
The critical difference between LP and HP HA sequences is located at the 
proteolytic cleavage site (PCS) (Garten et al, 1981, Klenk 1980, Lazarowitz et al 1973).  
The consensus amino acid sequence of the PCS in LP viruses is PQRETR/GLFG for the 
H5 subtype and PEXPKXR/GLFG for H7 viruses (Perdue et al, 1997).  In contrast, the 
PCS of HP viruses contains an increased number of basic amino acids (arginine and 
lysine); this change can occur through specific mutations or insertions of amino acids 
(Horimoto & Kawaoka 1994, Perdue et al, 1997, Senne et al, 1996, Wood et al, 1993).  
The additional basic amino acids at the PCS of HPAIV, allows cleavage to be completed 
with more widely found furin-like or subtilisin-like endoproteases (Garten et al, 1981, 
Horimoto & Kawaoka 1995, Rott et al, 1979).  This increases the ability of the virus to be 
cleaved in more tissues, leading to widespread infection.  In contrast, cleavage of the HA 
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molecule from LPAIV requires trypsin-like enzymes, limiting replication to the 
respiratory and intestinal tracts where enzymes are found. 
 LPAIV replicates in ducks predominantly in cells lining the gastrointestinal tract, 
leading to minimal or no clinical signs of infection, shedding of virus in high titers in the 
feces, and transmission via the fecal-oral route (Webster et al, 1978, Hinshaw et al, 
1979). Initial observations of HPAIV infection in ducks revealed a lack of morbidity and 
mortality, but since 1999, both HP H7 and H5 viruses have been isolated that can induce 
systemic spread of the virus in wild ducks, leading to neurological disease and death 
within one week of infection (Capua & Mutinelli, 2001, Ellis et al, 2004, Sturm-Ramirez 
et al 2004, 2005, Tang et al, 2009).  An additional feature of HPAIV infection in ducks is 
that higher titers of virus are shed from the respiratory tract than from the intestinal tract, 
indicating an evolution in tissue tropism (Sturm-Ramirez et al, 2004). 
The NA gene has also been suggested to play a role in pathogenesis after 
increased pathogenicity was seen in chickens infected with different strains of H5N1 
virus (Hulse et al, 2004).  In chickens, typical waterfowl AIV has adapted to include both 
a deletion in the stalk region of the NA coupled with increased glycosylation in HA 
(Matrosovich et al, 1999).  These nucleotide changes have been shown to precede 
increased pathogenicity in chickens (Perdue et al, 1995, Munier et al 2010, Giannecchini 
et al, 2010).  These same changes, when tested in mice, show decreased virulence 
(Castrucci & Kawaoka 1993) showing variability in host range. Other changes in host 
directed glycosylation also lead to enhancement of host cell proteases that allow 
increased sialidase activity, leading to more efficient spread of virus through host tissues 
(Schulman & Palese, 1977).   
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The NS gene has also been implicated in virulence based on separate amino acid 
differences located in the NS2 protein, which show increased virulence in chicken 
embryos (Perdue 1992).  Another amino acid change in the NS1 protein resulted in 
increased virulence in a H5N1 strain inoculated into chickens (Li et al, 2006).   
The viral polymerase gene PB2 also plays an integral role in virulence and host 
range, particularly with regard to the specific amino acid found at position 627.  It has 
been determined in mammalian-origin viruses that at position 627 the amino acid is 
lysine, where in avian-origin viruses that amino acid is glutamic acid (Subbarao et al, 
1993).  HP H5N1 and H7N7 viruses isolated from human patients have also shown a 
lysine at position 627, reflecting the adaptation from birds to humans (Puthavathana et al, 
2005, Fouchier et al, 2004).  This lysine contributes to the virulence of avian H5N1 
viruses by increasing neurovirulence and systemic spread of the virus to non-respiratory 
organs in mice (Hatta et al, 2001, Shinya et al, 2004).  Another amino acid change at 
position 701 of the PB2 protein of HP H5N1,  proved to be non-lethal in ducks but was 
found to show increased replication and lethality in mice, confirming its ability to 
contribute to virulence and be a host range factor (Li et al, 2005).  Overall, these 
observations show the many possibilities of separate influenza proteins having specific 
roles in increasing virulence and pathogenicity, and that those biologic properties are not 
the result of one gene acting alone, but a constellation of all the genes acting in concert. 
Transmission of avian influenza A viruses 
The ability of AIV to cross host species barriers depends on several factors.  
There needs to be direct interaction between 2 different species coupled with adequate 
exposure of virus either through direct or indirect contact.  The virus needs to have the 
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ability to enter the new host cells and replicate, as well as adapt to the new host 
successfully in order to be shed and transmitted to others within the new host species.  
The closer the hosts are genetically related, the easier it seems to be for influenza virus to 
infect and persist.  Intraspecies transmission is most common but interspecies 
transmission often occurs, and of course, then is the basis for the public health concern 
with HPAIV.  Increasing interactions of wildlife and domestic animals on farms and in 
live bird and animal markets, as well as increased transport of commercial and exotic 
species within and between continents, has led to more interspecies transmission. 
Some species are capable of being an intermediate host to transfer AIV from wild 
birds to other species.  Chickens are a common intermediate for wild bird AIV strains 
with the most common subtypes found in chickens being H3, H5, H6, H7, and H9 (Liu et 
al, 2003).   Chicken-origin viral sequences show distinct differences in their HA and NA 
genes that differ distinctly from wild waterfowl influenza A isolates, with increased 
glycosylation in the HA globular head region and NA protein, plus a deletion in the stalk 
region of the NA gene (Matrosovich et al, 1999, Hulse et al, 2004).    These adaptations 
can make the virus isolate more pathogenic to chickens (Perdue et al, 1995, Hulse et al, 
2004, Munier et al 2010, Giannecchini et al, 2010) and more transmissible to humans 
(Class et al 1998, Subbarao et al, 1998).  Since 2002, a majority of the Z genotype H5N1 
influenza viruses possess the same deletion in the NA stalk suggesting it has established 
itself in terrestrial poultry (Li et al, 2004). 
Swine have also been considered a good intermediate due to the existence of both 
SA-α-2,3-gal and 2,6-gal receptors in respiratory epithelial cells that allow them to be 
infected with both avian and human influenza viruses.  This also allows for the ability to 
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switch receptor specificity as the virus adapts in the swine host (Ito et al, 1998, Rogers & 
D‟Souza 1989).  These features have resulted in swine being labeled as the perfect 
„mixing vessel‟ for both avian and human influenza strains that could combine and 
mutate to create a more infectious influenza virus to humans.  Swine have also been 
responsible for transmitting swine H1 and H3 to turkeys housed on the same farm 
(Mohan et al, 1981, Suarez et al, 2003, Tang et al, 2005), providing yet another avenue 
for interspecies transmission. 
Quail are also an effective intermediate for AIV.  Characterization of sialic acid 
receptors present in quail have shown that they possess both SA-α-2,3 and α-2-6-gal 
(Matrosovich et al, 1999, Perez et al, 2003, Wan & Perez 2006, Kimble et al, 2010) 
allowing them to be infected with both avian and human viruses and adapt to switch 
receptors while replicating in the quail.  Experimental and natural infections show that 
quail can be infected with and transmit multiple HA subtypes of AIV to terrestrial poultry 
(Guan et al 1999, Cameron et al, 2000, Marakova et al, 2003, Perez et al, 2003, Sorrell & 
Perez 2007, Hossain et al, 2008, Giannecchini et al, 2010, Lee et al, 2010).  Quail can 
also support the replication of AIV subtypes H1-H14 as well as swine influenza viruses 
H1 and H3 (Marakova et al, 2003).  Pheasants also carry both SA-α-2,3 andSA-α-2-6 
receptors (Kimble et al, 2010) and are susceptible to infection with AIV HA subtypes 
H1-H15, and are capable of shedding virus for extended periods of time.  This makes 
them a concern for transmission of AIV in live bird markets or on wild game bird farms 
(Humberd et al, 2006).   
Equine influenza A viruses, like AIVs, prefer binding to SA-α2-3-gal (Rogers & 
Paulson 1983) and have directly transmitted equine influenza A H3N8 to dogs leading to 
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the establishment of this subtype in this species.  Studies in dogs have detected the 
presence of SA-α-2,3-gal receptors on the surface of bronchial and bronchiolar epithelial 
cells, but a lack of SA-α-2.6 (Song et al, 2008).  In this same study, avian-H3N2 virus 
was detected in dogs, showing their ability to be directly infected with both avian and 
equine influenza A (both SA-α-2,3-gal preference) viruses, but may limit the 
transmission from dogs to humans. 
As outlined previously, humans have SA-α-2,3-gal on ciliated cells in the lower 
respiratory tract.   This has allowed more recent avian H5N1 viruses, which still prefer 
SA-α-2,3-gal, to infect humans (Matrosovich et al, 1999, 2004, van Riel et al, 2006, 
Shinya et al, 2006), but not readily be transmitted human-to-human without the 
adaptation to SA-α-2,6-gal (Suzuki 2005).  This is of considerable importance, in that 
avian H5N1 viruses have yet to become transmissible among humans.  Adaptation of 
avian H5N1 virus to incorporate specificity for SA-α-2,6-gal may lead to the next human 
pandemic.   
Research with reverse genetics, that allows for changing specific nucleotides in 
specific genes, has elucidated two specific amino acid changes in the HA gene that can 
convert the SA receptor specificity from SA-α-2,3gal to SA-α-2,6gal.  These two specific 
amino acid changes are a serine to glycine at position 228, and a leucine to glutamic acid 
at position 226.   Both of these changes appear essential to allow human influenza A 
viruses to successfully replicate in the intestine of ducks (Vines et al, 1998). 
Another determinant of host range is the specific amino acid 627 of the PB2 
protein.  The change from a glutamic acid (avian) to a lysine (mammals) (Subbarao et al, 
1993) enhances the transmission from birds to mammals.  Once this change is established 
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in mammals it will present a threat for humans because it would enhance human to 
human transmission.  Another aspect of position 627 in PB2 is its role in temperature 
sensitivity.  When the PB2 627 is a lysine (human viruses), the viral polymerase complex 
is more likely to support replication from 33º C to 37º C, which is typical of human 
respiratory tract temperatures.  If the PB2 627 amino acid is glutamic acid (avian 
viruses), viral replication is hindered at temperatures of 33º C since temperatures in the 
duck intestinal tract are higher at 41º C.   This suggests the decreased ability of avian 
influenza viruses to efficiently replicate in humans, or human viruses in ducks, without 
adaptation (Massin et al, 2001). 
The NA protein also plays a role in host range.  The NA protein prefers to cleave 
the same sialosaccharides that the HA bound to initially, meaning NA prefers the same 
SA-α-2,3-gal for avian influenza viruses and SA-α-2,6-gal for human viruses (Baum and 
Paulson, 1991). 
Resistance of Avian Influenza Viruses to Antiviral Drugs 
While a multitude of vaccines have been made against different clades of H5N1 
virus, there currently is not one individual vaccine that will universally protect against all 
H5N1 clades and subclades.  Based on experience with the most recent pandemic of 
swine-origin H1N1 virus, we know there will be at least six months or more before a 
suitable vaccine can be created in the event of a pandemic. This leaves antiviral drugs at 
the forefront for treatment and control of a pandemic. Currently, there are only two 
groups of antiviral drugs that are approved for both treatment and prophylaxis of 
influenza virus infections: M2-ion channel inhibitors, the adamantanes, amantadine and 
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rimantadine, and the neuraminidase inhibitors, including oseltamivir, zanamivir and 
peramivir, the latter of which has been approved for use in certain medical situations.   
The first antiviral studied for treatment of infection with influenza A, was 
amantadine hydrochloride, with its antiviral effects first published in 1964 (Davies et al, 
1964)  The adamantanes work to block the function of the influenza A virus M2 protein, 
which  prevents viral uncoating in the infected cell (Wang et al, 1993).  Adamantanes 
also cause an altered conformation of the hemagglutinin protein which prevents release of 
virus from the host cell (Grambas and Hay, 1992, Betakova et al, 2005). Amantadine 
hydrochloride continued to be the drug of choice for treating H3N2 infections and was 
licensed for this purpose in 1976. Another adamantane derivative, rimantadine was 
licensed in 1993 for use as an influenza antiviral. Both adamantine derivatives can be 80-
90% effective and diminish symptoms by 1.5 days if taken within 48 hours after 
symptom onset (Oxford and Galbraith, 1984, Reuman et al, 1989, Younkin et al, 1983).  
Unfortunately, both amantadine and rimantadine are not effective against influenza B 
viruses and both have been shown to have significant side effects in humans during the 
course of treatment (Hayden et al, 1980, Dolin et al, 1982, Hayden et al, 1983).  The 
widespread use of adamantanes led to the rapid development of resistant strains, either 
following drug treatment or naturally through evolution (Hayden and Hay 1992, Bright et 
al, 2005, Deyde et al, 2008). Since development of widespread resistance to 
adamantanes, neuraminidase inhibitors were evaluated to control influenza virus 
infections and currently provide the most effective antiviral treatment (Fiore et al, 2007).  
Neuraminidase inhibitors were designed to be a valuable drug target because NA 
is directly involved in the propagation of influenza virus.  Also, the specific amino acids 
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in the NA active site that interact with the substrate or that are in the general area of the 
active site are strictly conserved among influenza A and B strains (Burmeister et al, 1993, 
Varghese et al, 1998).  The important amino acids at the active site can be divided into 
two groups: the catalytic residues (R-118, D-151, R-152, R-224, E-276, R-292, R-371, 
and Y-406) that have direct contact with the substrate, and the framework residues (E-
119, R-156, W-178, S-179, D-198, I-222, E-227, E-277, N-294, and E-425) that play a 
role in the stabilization of the active site structure (Coleman et al, 1983).  The idea that 
using an inhibitor that so closely resembled the natural substrate, was expected to avoid 
the selection of drug-resistant mutants (Varghese et al, 1998).  Those drugs currently 
licensed for treatment are inhaled zanamivir (2,4-dideoxy-2,3-didehydro-4-guanidino-
sialic acid) (Relenza
TM
) and oral oseltamivir phosphate (OP) (Tamiflu®). OP is the 
prodrug which is converted in the liver of humans to the active metabolite oseltamivir 
carboxylate (OC) (ethyl-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-
carboxylate). Alterations in design of the two drugs allow them to interact with different 
amino acid residues in the NA active site. OP has an affinity for a positively charged and 
hydrogen binding environment created by the catalytic amino acid residues R118, R292, 
and R371.  Zanamivir interacts with a negatively charged region formed by the 
framework residues E227 and E119 (Ferraris & Lina 2008).  Both oseltamivir and 
zanamivir interact with the catalytic residue R152 but zanamivir is more likely to interact 
with R224 and E276 based on a specific glycerol side chain (Yen et al, 2006, McKimm-
Breschkin 2000, Smith et al, 2002, Stoll et al, 2003).  Neuraminidase inhibitors (NAIs) 
work to interfere with the normal function of influenza virus neuraminidase and to limit 
viral infection by blocking the enzyme active site leading to inhibition of its sailidase 
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activity.  NAIs also work by preventing the release of virus from the infected host cell 
(von Itzstein et al, 1993, Hsieh et al, 2007, Gubareva et al, 2000)   NAIs can also cause 
aggregation of the virus if released from the host cell preventing the virus from 
penetrating into mucous secretions and spreading to nearby cells (Roberts and Govorkova 
2009).   
Problems with Antiviral Drug Resistance 
In vitro studies have revealed that continued passage of virus in the presence of 
NAIs lead to the emergence of resistant strains of virus (McKimm-Breschkin 2000, 
Bantia et al, 1998, Molla et al, 2002, Hurt et al, 2009).  Cell culture testing of NAIs have 
shown variable propensity to evolve resistance among different viruses (Woods et al, 
1993) which makes comparison testing between laboratories difficult, and animal models 
valuable tools. 
Development of resistance in vivo was detected in a ferret model following H3N2 
challenge and treatment with amantadine but not zanamivir (Herlocher et al, 2003) In 
vivo resistance was also detected following oseltamivir treatment and H5N1 infection in 
the ferret model (Govorkova et al, 2007).  This suggests the potential of developing 
resistance but not the probability of occurrence. Finally, studies from human clinical 
trials, treatment during natural infection, natural infection without treatment, and 
surveillance in avian strains have shown an increase in oseltamivir resistance from both 
LPAIV as well as HPAIV such as H5N1 (Gubareva et al, 2001, Kiso et al, 2004, Le et al, 
2005, deJong et al, 2005, McKimm-Breschkin et al, 2007, Sheu et al, 2008, Hauge et al, 
2009, Boltz et al, 2010).  The increased detection of seasonal human influenza virus 
strains showing resistance to oseltamivir is of great concern.  The predominant mutation 
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of H274Y in N1 subtypes, detected from America to Europe to Asia, is puzzling in that 
regional drug use is not suspected to be the problem (Sheu et al, 2008, Dharan et al, 2009, 
Meijer et al, 2009, Hurt et al, 2009, Hauge et al, 2009).  
Current usage statistics do not show clear connections between oseltamivir usage 
and the increase in oseltamivir resistant strains.  For example, Japan, which had the 
highest reported prescription rates (70.9 for every 1,000 people in 2005, Yasui et al, 
2007), reported that only 3% of tested H1N1 strains were oseltamivir resistant (WHO, 13 
June 2008). The next highest prescription usage in 2005 was in Germany (~5.5 
prescriptions per 1,000 people, but dropped to usage of <2 prescriptions/1,000 people by 
2007) where it was reported that 13.1% of tested strains were oseltamivir-resistant 
(Kramarz et al, 2009).  Norway was one of two countries with the highest rates of 
oseltamivir resistance, reporting resistance to oseltamivir during the 2007-8 season at 
67.4% of tested strains, despite the fact that less than 1 prescription/1000 people was 
reported in 2006 and 2007. The second highest increase in resistant strains was reported 
in Belgium, where a rate of 53.1% resistance was reported, but with less than 1/1,000 
prescriptions in 2006 and less than 2/1,000 in 2007 (Kramarz et al, 2009).  Since 
oseltamivir resistance is showing a natural evolution of resistance rather than resistance 
primarily driven by drug usage, it is important to understand what molecular changes are 
taking place within the NA gene that are associated with this functional change.   
It is important to both evaluate the affinity of NA for its substrate and inhibitors, 
as well as its relation to the receptor binding affinity to HA.  Once there is a better 
understanding of the kinetics, the role of genetic changes can be better elucidated.  
Recent analysis of H1N1 virus strains with the H274Y mutation from the 2007-08 flu 
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season report an increase in affinity of N1 NA for its substrate and inhibitor and moderate 
genetic changes that may play a role in this change.  The changes of importance are that, 
except for one resistant virus, all sensitive and resistant strains were in the same clade, 
thus sharing their evolutionary background.  Other mutations new to the 2007-08 season 
were H45N, K78E, E214G, R222Q, G249K, T287I, K329E, and D344N (Rameix-Welti 
et al, 2008).  Amino acids at position 45 and 78 are located in the NA stalk region and are 
not suspected to play a significant role in resistance.  In contrast, those at positions 222, 
249, and 344 are located near the catalytic site (H5N1 structure, Russell et al, 2006) and 
may alter NA substrate affinity (Rameix-Welti et al, 2008).  This shows that there are 
increasing evolutionary changes taking place within the NA that, in conjunction with HA 
and the other six genes, are contributing to an increase in oseltamivir resistance. 
This documented increase in resistance has lead researchers to evaluate other 
options for development of new antiviral compounds to combat influenza virus 
infections, as well as re-evaluate the current drugs that are stockpiled for a potential 
pandemic. 
Investigational compounds for Influenza 
Peramivir, a newer NAI, was designed utilizing a novel approach to create a more 
orally bioavailable drug than oseltamivir.  Based on protein crystallography, peramivir 
was created as cyclopentane derivative with additions including a negatively charged 
carboxylate group, a positively charged guanidino group and lipophilic side chains (Babu 
et al, 2000). Peramivir was shown to be more beneficial than oseltamivir in animal 
studies when given orally and exhibited more potent viral inhibition by decreasing death 
rates and lowering viral lung titers (Babu et al, 2000, Bantia et al 2001, Drusano et al, 
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2001, Smee et al, 2001, Sidwell et al, 2001, Govorkova et al, 2001, Sweet et al, 2002) 
Initial clinical trials in humans discovered low bioavailability when administered orally, 
(Barroso et al, 2005) opening the prospect of parenteral administration of the drug.  
Parenteral administration of the drug would also be beneficial in reducing the dosing 
levels when compared to traditional oral oseltamivir dosing.  Intramuscular treatment of 
mice with Peramivir demonstrated reduced weight loss and mortality after infection with 
H1N1 and H3N2 subtypes (Bantia et al, 2006), and was effective against H5N1 in both 
mice and ferrets (Boltz et al, 2008, Yun et al, 2008).  Phase II and phase III trials have 
been carried out with intravenous administration of peramivir in humans, and this 
treatment was shown to reduce clinical symptoms and show a significant reduction in 
viral titers (Kohno et al, 2009, Ison et al, 2009). Peramivir is not recommended for 
treatment when oseltamivir resistance is known or suspected as it follows the same 
resistance patterns (Baz et al, 2007). Intravenous zanamivir is currently in phase II 
clinical trials and can currently be used in emergency situations with critically ill patients.  
Zanamivir has also been shown to effectively treat oseltamivir resistant viruses (Roberts 
and Govorkova, 2009) as a second line of defense.  Laninamivir, another NAI was 
designed to be a high-potency drug to minimize the high number of doses needed with 
traditional treatment with oseltamivir or zanamivir, and works as a long lasting 
neuraminidase inhibitor that can be administered once weekly.  Laninamivir has been 
shown to be more effective than zanamivir in a mouse model and was found to be longer 
acting, with higher retention rates, in tissues following inhalation (Honda et al, 2009, 
Koyama et al, 2009).   
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Ribavirin (Virazole), a nucleoside analogue, which has limited use in certain 
countries, is a polymerase inhibitor that inhibits RNA synthesis against both influenza A 
and B viruses (Witkowski 1972, Sidwell et al, 1972, Oxford 1975, Scholtissek 1976, 
Eriksson et al, 1977).  One limitation of ribavirin is that at high doses or chronic use, 
hemolytic anemia has been induced (Canonico et al, 1984, Page and Connor, 1990).  
Viramidine, a prodrug of ribavirin is being investigated further and was found to have 
lower toxicity, better targeting of the liver for conversion, and also limits the amount of 
drug localizing in red blood cells (Lin et al, 2003, Sidwell et al, 2005).  Favipiravir (T-
705), a pyrazine derivative, is a novel polymerase inhibitor that is orally active, and has 
shown anti-influenza activity both in vitro and in vivo (Furuta et al, 2002, Takahashi et al, 
2003, Furata et al, 2005, Sidwell et al, 2007, Furuta et al, 2009, Smee et al, 2009, Kiso et 
al, 2010, Sleeman et al, 2010) against influenza A, B, and C viruses.  Favipiravir differs 
from ribavirin in that it does not interfere with host DNA or RNA synthesis, rather 
inhibits the viral RNA polymerase during early to middle stages of infection, and it is less 
cytotoxic (Furata et al, 2002, Furuta et al, 2005).  Fivipiravir was found to be more 
therapeutic in the mouse model against influenza A than oseltamivir, with increased 
survival and decreased viral lung titers (Furuta et al, 2002, Takahashi et al, 2003).  Mice 
treated with high doses of fivipiravir were also protected against HP H5N1 viruses 
including oseltamivir-resistant HP H5N1 viruses, even when drug treatment was delayed 
up to 72-96 hours post infection (Sidwell et al, 2007, Kiso et al, 2010).   
Cyanovirin-N (CV-N) is a virucidal protein that comes from the cyanobacterium 
Nostoc ellipsosporum. CV-N targets the high mannose oligosaccharides on influenza 
glycoprotein HA1 directly, via protein-carbohydrate interactions that inactivate the viral 
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particle thus preventing it from entering the host cell (O‟Keefe et al, 2003).  CV-N is 
known to have potent inhibitory activity against many influenza A and B strains but may 
be limited in use with influenza strains that acquire certain mutations in the 
hemagglutinin gene that lack glycosylation patterns leading to reduced CV-N binding 
(O‟Keefe et al, 2003, Smee et al, 2007).  CV-N studies in mice show reduced mortality 
and pneumonitis and in ferrets, reduced viral titers in nasal washes collected following 
intranasal delivery of drug (Smee et al, 2008).  DAS181 is a recombinant fusion protein 
containing a saliadase derived from Actinomyces viscosus and a respiratory epithelium-
anchoring domain (Malakhov et al, 2006).  The saliadase works to remove sialic acids in 
respiratory epithelium cells, which normally serve to bind the virus, thus inhibiting or 
causing a reduction in infection.  Mice studies have shown protection from death using 
intranasal treatment of DAS-181 (Triana-Baltzer et al, 2009).  
Thiazolides are a class of drugs initially discovered to treat parasitic infections.  
Nitazoxanide, is a thiazolide liscensed to treat entiritis of Cyrptosporidium parvum and 
Giardia lamblia, but was recently tested against several influenza A strains in vitro.  
Nitazoxanide works by a novel mechanism that appears to interfere with the maturation 
process and blocks intracellular transport of the viral hemagglutinin, keeping the virus 
from being transported to the cell surface (Rossignol et al, 2009).  
Small interfering RNAs (siRNA) have also been evaluated as a treatment to 
control influenza virus infection.  RNA interference (RNAi) occurs when double stranded 
RNA (dsRNA) is injected into a subject and specifically silences sequence-specific 
regions of a gene (Fire et al, 1998) or causes sequence specific degredation of 
homologous mRNA (Hannon 2002).  siRNA treatment has proven beneficial in influenza 
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infection both in vitro by showing potent inhibition of influenza virus production with 
influenza A H1N1 suptypes (Ge et al, 2003), and in vivo with increased survival and 
inhibition of viral replication with treatment prior to lethal challenge from H1N1, H5N1 
and H7N7 (Tompkins et al, 2004).  Sequence homology between the gene target and the 
siRNAs was crucial for protection and may not be valuable with certain influenza viruses 
that would contain mismatches from the siRNAs (Tompkins et al, 2004).   While these 
aforementioned drugs are still in developmental and clinical trial phases, it is necessary to 
focus on better understanding the abilities and outcomes of the usage of the most 
commonly stockpiled drug, oseltamivir. 
Efficacy of Oseltamivir in Human and Animal Models 
Oseltamivir was initially designed following development of zanamivir in order to 
create a more orally bioavailable drug for treatment of influenza virus infections.  Initial 
studies were carried out with both oseltamivir carboxylate and its ethyl ester prodrug 
oseltamivir phosphate, with the latter being much more orally bioavailable in humans (Li 
et al, 1998, Mendel et al, 1998).  Initial treatment studies in mice led to a significant 
reduction in viral titers in the lung and enhanced survival when infected with influenza A 
and B viruses. Studies using ferrets also demonstrated reduced viral titers in nasal washes 
and elimination of typical signs of distress seen during influenza virus infection (Mendel 
et al, 1998).  OP was also well tolerated in treated animals and showed no signs of 
toxicity.  Along with efficacy, oseltamivir was also tested in mice to evaluate the immune 
effects associated with this specific neuraminidase inhibitor.  Cytotoxic T lymphocytes 
(CTL) and natural killer (NK) cells were evaluated for their presence both in influenza 
infected mice and uninfected mice during treatment with oseltamivir.  Results confirmed 
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that oseltamivir treatment had no adverse effects on the primary cellular immune 
response to influenza infection (Burger et al, 2000).  Mice that survived were also re-
challenged with influenza virus and were able to survive due to adequate neutralizing 
antibodies, showing that oseltamivir did not interfere with the ability of the mice to 
develop an ample humoral response to the virus (Burger et al, 2000).   
Following the outbreak of HP H5N1 viruses, oseltamivir was re-evaluated to 
confirm its efficacy for treatment against these HP strains.  In animal models, varying 
levels of protection have been shown through the use of oseltamivir to protect mice and 
ferrets from death after challenge with HP H5N1 viruses (Govorkova et al, 2001, 2007, 
2009, Yen et al, 2005, Ilyushina et al, 2008). Some concerns that arose during these 
studies with oseltamivir focused on the need for appropriate timing of drug delivery and a 
dose dependency required for different HP H5N1 strains (Ilyushina et al, 2008).  These 
studies show that the longer the treatment (8 days versus 5 days), and the higher the dose 
(10mg/kg/day vs. 1 or 0.1mg/kg/day), the better the survival rate and more significant the 
decrease in viral replication in the host. Similar studies to confirm the optimal dosage of 
oseltamivir necessary to protect against lethal infection and to minimize the severity of 
disease were also determined for HP H5N1 in the ferret model (Govorkova et al, 2007). 
Ferrets in this study received either a prophylactic dose or delayed treatment of 
oseltamivir; it was confirmed that the dosage of oseltamivir needed to protect the ferrets 
from lethal challenge was higher than the current recommendations for humans, 
depending on strain of H5N1 used for challenge. This is of some concern since delayed 
treatment is commonly reported for humans and, depending on the strain of virus, 
frequently has led to decreased viral loads but not full protection from death. Further 
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evaluation of differing treatments in ferrets led to the observation that oseltamivir 
resistance can arise following drug treatment.  Evaluation of three different samples 
(lung, brain, and nasal wash; 10 individual clones from each) from ferrets revealed 1 of 
10 clones in the lung of animals treated with 10mg/kg/day, and 1 of 10 clones in the brain 
of those treated with 25mg/kg/day, to have acquired the H274Y mutation which is known 
to confer resistance to oseltamivir. The authors of this study concluded that direct 
sequencing and plaque reduction assays were not adequate by themselves to detect the 
mutations, but that analysis of individual plaques was adequate to determine that 
mutations occur (Govorkova et al, 2007). This is only a small representation of the 
possible clones recovered and needs to be further addressed.  
Resistance to oseltamivir has been observed in humans infected with HP H5N1 
following treatment with oseltamivir (de Jong et al, 2005, Le et al, 2005. Le et al, 2008). 
Some concerns with these observations are both the timing of drug treatment and the 
timing of collection of samples. First, one patient was not given oseltamivir until at least 
48 hours after infection. The other cases had treatment started well after the optimal time, 
which would be within 48 hours of onset of symptoms. Unfortunately, an initial specimen 
was not collected before treatment from the one patient with optimal drug dosage, so 
confirmation of whether she had the resistance mutation of H274Y before treatment or 
whether it evolved during treatment could not be confirmed. Another patient that did 
show the resistance mutation after treatment but not before showed a possible small 
subset of the wild-type sequence along with the mutant sequence, suggesting that  the 
mutant sequence may not be fit enough to continue adequate replication and lead to 
effective transmission, which is of concern if it is to become a pandemic.  In a recent 
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reverse genetics study, the replication efficiency and pathogenicity of HP H5N1 strains in 
mice documented an alteration to include the H274Y and N294S mutations; the mutated 
virus retained its lethality to mice and retained replication efficiency in vitro (Yen et al, 
2007).  Another NA resistant mutation, E119V, has been shown to retain replicative 
ability and transmissibility as efficiently as wild type virus (Herlocher et al, 2004, Yen et 
al, 2005), whereas another mutation, R292K, appears to be compromised both in vitro 
and in vivo and had limited ability to transmit in the ferret contact model (Herlocher et al, 
2002, Yen et al, 2005).   Seasonal H1N1 viruses with the H274Y mutation have shown 
restriction in replicative ability and transmission in ferrets (Ives et al, 2002), but the virus 
has the ability to be transmitted if infectious doses are increased (Herlocher et al, 2004). 
Viral fitness has been analyzed utilizing a competitive-mixtures model in ferrets 
(Hurt et al, 2010).  The premise was to evaluate the outcome of infecting ferrets with both 
wild-type and oseltamivir resistant virus of the same subtype at differing percentages to 
determine if one virus or the other will win out while in competition within the host.  
Results show that the R292K mutated virus was outgrown by the R292 wild-type virus 
and was not transmissible which is consistent with previous studies with this mutation.  
The H274Y mutated virus was only marginally outgrown by the H274 wild-type virus, 
but was equally transmissible among ferrets which has been variable in previous studies.  
Recent evidence has also shown that those strains resistant to oseltamivir can be 
efficiently transmitted by direct contact through guinea pigs. (Bouvier et al, 2008) 
Current research indicates that mice, when infected with swine H1N1 followed by 
treatment with OP 1 hour post infection, had reduced viral titers in the lung at days 3 and 
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6 post-infection (Itoh et al, 2009). Analyzing the virus after treatment was not addressed 
in this experiment, nor was the effect of delayed treatment post-infection. 
Chickens have also been evaluated for protection from HP H5N2 virus following 
treatment with oseltamivir and zanamivir (Meijer et al, 2004).  Oseltamivir was able to 
reduce infection and transmission levels but did not completely prevent it while 
zanamivir proved to have no effect on infection or survival (Meijer et al, 2004).  One 
interesting aspect of the study showed that 3 contact chickens in the oseltamivir group 
become positive after cessation of treatment, suggesting length of treatment may be 
important and play a role in transmission. 
All this is of some concern as the stockpiling of the most orally bioavailable drug 
oseltamivir is at a peak. Since human patients are now more aware of antivirals coupled 
with recent concerns regarding the most recent pandemic of swine-H1N1, we can expect 
that this will ultimately lead to a higher use of the drug.  It is imperative that we better 
understand the possible outcomes of resistance from antiviral treatment including the 
possibility of oseltamivir contamination in the environment from excessive use. 
Oseltamivir in the Environment 
Recent interest has been shown in the inability of OC to be removed or degraded 
by natural environmental conditions or sewage treatment plants (Singer et al, 2007, 
Bartels and von Tumpling jr, 2008, Fick et al, 2007, Straub 2009, Hutchinson et al, 2009, 
Ghosh et al, 2010a) suggesting a potential for environmental build-up. The prodrug 
Tamiflu is given orally as OP. OP breaks down in the liver of humans to the active 
metabolite OC. OC is not broken down any further and 80% is renally excreted as OC 
(Ward et al, 2005). While OC has been shown to be poorly orally bioavailable, it is not 
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known to what extent the interaction in the gastrointestinal tract of infected animals may 
have on the selective pressure of the virus.  
The hypothesis of this outcome is that OC will enter the regional aquatic 
environment, such as lakes, streams and rivers, and will be found at high levels in areas 
of high human treatment use. Proposed suggestions show that OC can remain in the 
environment for up to 18 days and remain at levels of 0.08-0.23 μg L-1.(Singer et al, 
2007, Bartels and von Tumpling jr 2008) A suggestion of the highest predicted 
environmental concentration (PEC) was also proposed for Japan, a country which 
currently uses a large amount of oseltamivir, to be 0.028 μg L-1.(Bartels and von 
Tumpling jr 2008) These are proposed values only, as different issues such as water size, 
prescribed amounts of oseltamivir, and the actual spread of a pandemic would all play a 
role in actual numbers and outcomes.  
More recently, actual OC levels were determined in areas of Japan that show high 
levels of prescribed Tamiflu®. Values of OC measured before the 2007-2008 influenza 
season were undetectable in the Yodo river system, but levels of 2-58 ng/L were 
measured during the influenza season (Söderström et al, 2009). The highest levels 
detected in Japan during the 2008-2009 influenza season were 293.3 ng/L of OC at its 
peak from sewage treatment plant discharge, with river water levels of OC ranging from 
6.6-190.2 ng/L (Ghosh et al, 2010b). These proposed and actual outcomes show the need 
for research into what extent the overuse of oseltamivir and build-up of OC or OP in the 
environment contributes to the emergence of resistant virus strains, and the impact that 




We know that influenza viruses are evolving in many species alarmingly fast.  
While great strides have been made in increasing surveillance in both humans and avian 
species, there are still a vast number of unknown factors present.  Since wild birds are the 
only known reservoir to harbor all subtypes of influenza A viruses, it is valuable to study 
and evaluate issues that directly concern wild birds, including the viruses they carry and 
the impact that environmental contamination with antiviral drugs has on the species as a 
whole.  Understanding these factors will help predict the eventual impact on humans in 
terms of virus transmission.  Influenza A viruses resistant to oseltamivir  have been 
detected at an increasing rate in humans, forcing us to re-evaluate the potential dangers 
associated with stockpiling only this drug, as well as possible outcomes of mass human 
use in the event of a pandemic.  The knowledge that oseltamivir has already been 
detected in the environment formulated the basis for the proposal to study what may 
happen to viruses in our avian reservoirs when they ingest varying quantities of 
oseltamivir from the environment.  We sought to determine whether emergence of more 
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CHAPTER 2: TRANSMISSION OF AVIAN INFLUENZA A VIRUSES AMONG 
SPECIES IN AN ARTIFICIAL BARNYARD 
Summary 
Waterfowl and shorebirds harbor and shed all hemagglutinin and neuraminidase 
subtypes of influenza A viruses and interact in nature with a broad range of other avian 
and mammalian species to which they might transmit such viruses.  Estimating the 
efficiency and importance of such cross-species transmission using epidemiological 
approaches is difficult.  We therefore addressed this question by studying transmission 
of low pathogenic H5 and H7 viruses from infected ducks to other common animals in a 
quasi-natural laboratory environment designed to mimic a common barnyard.  Mallards 
(Anas platyrhynchos) recently infected with H5N2 or H7N3 viruses were introduced 
into a room housing other mallards, in addition to chickens, blackbirds, rats and pigeons.  
Transmission was assessed by monitoring virus shedding (ducks) or seroconversion 
(other species) over the following 4 weeks.  Additional animals of each species were 
directly inoculated with virus to characterize the effect of a known exposure.  In both 
barnyard experiments, virus accumulated to high titers in the shared water pool.  The 
H5N2 virus was transmitted from infected ducks to other ducks and chickens in the 
room either directly or through environmental contamination, but not to rats or 
blackbirds.  Ducks infected with the H7N3 virus transmitted directly or indirectly to all 
other species present.  Chickens and blackbirds directly inoculated with these viruses 
shed significant amounts of virus and seroconverted; rats and pigeons developed 
 68 
antiviral antibodies, but, except for one pigeon, failed to shed virus at detectable levels. 
 
Introduction 
Gaining a more detailed understanding of the transmission potential of different 
avian influenza viruses among co-habitating species will enhance our ability to develop 
accurate models for disease spread, develop control strategies and, in some cases, assess 
risk of transmission to humans.  Influenza A viruses are a common concern among 
many animal species including, birds, horses, pigs, sea mammals and humans, as the 
effects of infection can range from asymptomatic to severe respiratory distress leading 
to death.  While avian influenza viruses (AIVs) are maintained in wild water birds, they 
occasionally spread to other animals and humans and can lead to public health concerns, 
as currently is the case for highly pathogenic H5N1 viruses.  All 16 hemagglutinin (HA) 
and 9 neuraminidase (NA) subtypes of influenza A virus are found in wild waterfowl 
and shorebirds (Webster et al, 1992, Rohm et al, 1996, Fouchier et al, 2005), but a much 
more restricted subset of these viruses is found in other birds and mammals.   
Most strains of AIV are designated low pathogenic (LP) and cause minimal 
illness in chickens as well as in wild waterfowl and shorebirds, but infection results in 
high levels of virus shedding, efficient spread among susceptible hosts, and perpetuation 
of the agent. Other AIV strains are classified as highly pathogenic (HP) and are 
restricted to members of the H5 and H7 subtype.  HPAIV classification comes from the 
ability to cause severe morbidity and mortality in domestic fowl, and more recently has 
caused mortality in wild waterfowl, mammals, and humans (Chen et al, 2004, Sturm-
Ramirez et al, 2004). In several outbreaks of HPAIV, circulation of a H5 or H7 LPAIV 
was detected shortly before the HPAIV outbreak of the same subtype, and was 
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determined to have evolved from the LPAIV strain either through a recombination event 
(Suarez et al, 2004, Hirst et al, 2004) or a gradual increase in virulence over time 
through the insertion or substitution of basic amino acids at the HA cleavage site 
(Kawaoka et al, 1984, Horimoto et al, 1995). 
Among water birds, mallards are of great interest due to their widespread 
distribution, reservoir for subtypes H1-H12, and ability to shed large amounts of virus 
with minimal pathology and disease (Munster et al, 2007, Keawchareon et al, 2008).  
Mallards can also travel large distances and have been implicated as carriers of AIVs 
from one region to another (Nagy et al, 2009, Brochet et al, 2010).  While it has been 
shown that shedding time decreases during a season of sampling, likely due to transient 
immunity (Latorre-Margalef et al, 2008), the concern remains that while infection and 
shedding continue to occur, the ability of LPAIV to mutate or evolve into HPAIV 
remains.  Furthermore, some HP H5N1 viruses are non-pathogenic in mallards 
(Keawcharoen et al, 2008) or can become non-pathogenic through evolutionary 
adaptation in the duck host, while remaining highly pathogenic to other domestic 
poultry.  This would allow for the possibility of ducks transmitting the virus to other 
poultry without themselves suffering from disease (Hulse-Post et al, 2005).  
The relative roles of direct contact versus environmental contamination in the 
transmission of AIVs remains poorly understood; both mechanisms likely occur based 
on experimental and field studies (Markwell & Shortridge 1982, Sivanadan et al, 1991, 
Laudert et al, 1993, Forrest et al, 2010).  Understanding routes of transmission is 
important to modeling spread of virus (Breban et al, 2009, Rohani et al, 2009, Roche et 
al, 2009).  AIVs have been shown to persist in water sources (Stallknecht et al, 1990, 
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Brown et al, 2007) and may provide a source of contamination to other species sharing 
the same source.  It has also been shown that over a 4 year period in Hong Kong, virus 
was isolated throughout the year from domestic ducks (Shortridge 1982).   
Common concerns with transmission of AIV from waterfowl to other species 
arise when one observes interactions of multiple species, both domestic and wild, 
present within a single small farm virtually anywhere in the world.   Transmission to 
species such as rodents would not likely result in disease spread, due to lack of 
detectable shedding, but could be exploited to monitor disease incursion via 
serosurveillance.  Rats and mice are found in abundance on small farms and are of 
concern due to their ability to move freely from outside into enclosures, and their 
propensity to eat and drink from common containers of poultry feed.  Although rats are 
not considered reservoir hosts for influenza viruses, both laboratory and cotton rats have 
been shown to replicate unadapted avian and human influenza A viruses (Ottolini et al, 
2005, Eicherberger 2007, Shortridge et al, 1998).  Similarly, pigeons are not generally 
considered an important host for transmission of influenza viruses, but are ubiquitous on 
small farms and undoubtedly exposed to these viruses on a routine basis.  Their 
susceptibility to experimental infection with both LPAIV or HPAIV has been variable 
(Fang et al, 2006, Werner et al, 2007, Jia et al, 2008, Brown et al, 2009). 
It is clear that wild and domestic ducks harbor and shed influenza A viruses and 
recurrently interact in nature with a broad range of other avian and mammalian species 
to which they might transmit such viruses.  Estimating the efficiency and importance of 
such multispecies transmission using epidemiological approaches is difficult.  We 
therefore addressed this question by studying transmission of LP H5 and H7 viruses 
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from infected ducks to other common animals in a quasi-natural laboratory environment 
designed to mimic a common barnyard. 
 
Materials and Methods 
Ethics Statement 
 All experiments were approved by the Institutional Animal Care and Use 
Committee of Colorado State University, Fort Collins, Colorado, USA, under approval 
number 09-168A. 
Animals 
Mallard ducks and chickens were purchased from local producers at 2-4 months 
and 3-4 weeks of age respectively.  Red-winged blackbirds and pigeons were captured 
locally.  Sprague Dawley rats, 6-8 weeks of age were obtained from Charles River 
Laboratories.  All animals tested negative for group-specific antibodies to influenza A 
virus by ELISA and strain specific antibodies (H5 and H7; <10) by hemagglutination 
inhibition (HAI) assay prior to infection.  
 
Viruses, Virus Assays and Serologic Assays 
 The viruses used in this study were A/Mallard/MN/346250/00 (H5N2) and 
A/Ruddy turnstone/ReedsBeachNJ/00 (H7N3).  Both viruses were propagated to 
passage three in 10 day old specific pathogen free embryonated chicken eggs (Sunrise 
Farms, NY).  Allantoic fluid was harvested 48 hours after inoculation, aliquoted, and 
stored at -80 C until use.  Both viruses were titrated by plaque assay using MDCK cells. 
(ATCC, Manassas, VA) 
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Subtype-specific antibodies were assayed by hemagglutination-inhibition assay 
(Kendal et al, 1982), using sera treated with receptor destroying enzyme (Denka Seiken, 
Tokyo, Japan) as previously described (Tyrrell & Horsfall, 1952).  Serial 2-fold 
dilutions of sera in PBS were prepared in 96-well V-bottom plates and mixed with 0.5% 
chicken red blood cells; titers of 10 or greater were considered positive.  Group specific 
antibodies were detected using a commercial ELISA test (Flu DETECT® BE, 
Synbiotics Corporation, Kansas City, MO) based on detection of antibodies to a 
recombinant AIV nucleoprotein antigen.  
 
Barnyard Transmission Experiment 
Two independent experiments were conducted using different influenza viruses.  
In the first experiment, the barnyard contained 8 ducks, 8 chickens, 8 rats and 10 
blackbirds.  The second experiment consisted of 8 ducks, 8 chickens, 6 pigeons, 5 
blackbirds and 7 rats.  In both experiments, animals were allowed to freely range inside 
a room within an ABSL3 facility.  The room had dimensions of 12 (width) x 18 (length) 
x 12 (height) feet and basic illumination was provided through a skylight in the roof.  
The barnyard rooms contained a plastic children's swimming pool (4 feet diameter, cut 
to 6 inches height) and 2 large bowls that contained commercial duck and chicken layer 
feed (Figure 2.1A).  Three smaller bowls filled with songbird mixed grains were 
suspended approximately 6 feet off the floor from pipes that ran longitudinally across 
the room; these pipes also served as perches for the blackbirds and pigeons.   Straw was 
spread across the floor sparsely and a sawhorse was present to provide additional 
perching opportunities for blackbirds and pigeons.  Two or three cardboard boxes were 
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provided as nest boxes for the rats. The pool was filled daily (but not emptied within the 
first week of the trial) with 5 gallons of water that had been sitting at room temperature 
and aerated with an aquarium pump for 24 hours to dechlorinate and thus prevent 
inactivation of any influenza virus (Rice et al, 2007).  This was also done to better 
mimic the natural state of water such as lakes and streams and farm water, which are 
typically not chlorinated.  In the first experiment, night vision (infrared) cameras were 
installed in the room to allow monitoring of behaviors in the dark (Figure 2.1B). 
 
 
Figure 2.1.  Barnyard room layout observed during the day (A) and at night (B). 
 
          On day 0 of each experiment, four ducks were removed from the barnyard room, 
placed in a separate room, and inoculated orally, intranasally and ocularly with 10
6
 
PFU/0.5 ml of the respective virus.  After 4 hours, the 4 inoculated ducks were returned 
to the barnyard where all animals were free to move about the room and interact.  All 8 
ducks (4 inoculated and 4 non-inoculated) were sampled on days 0-7 by collecting oral 
and cloacal swabs into 2 ml BA-1 medium (MEM, 1% bovine serum albumin, 350 mg/L 
sodium bicarbonate, 50ml/L 1M Tris, pH7.6, 5mg/L phenol red) supplemented with 
A B 
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antibiotics (gentamicin 50 ug/ml, polymyxin B 100 U/ml, nyastatin 50 U/ml, penicillin, 
100 U/ml and streptomycin 50 ug/ml), refrigerated and tested within 2 days for virus 
titer by plaque assay on MDCK cells; titers are reported as PFU/ml.  The only barnyard 
animals to have daily swab samples collected for virus titration were ducks as we 
wished to minimize the stress on remaining barnyard species and use seroconversion as 
the determination of virus infection.  All animals in the barnyard room were bled on 
days 0, 14, 21 and 28, and those sera were tested for seroconversion using HAI and 
ELISA. 
Two to 3 water samples were collected daily before the addition of new water. 
Samples were collected by skimming the top of the pool with a tube, by running the tube 
along the bottom of the pool to collect sediment, and, collecting splashed water from the 
floor near the pool if present.  To assist in interpreting pool water virus titers, we 
conducted an in vitro experiment in which pool water from a room containing non-
infected ducks was spiked with the H5 or H7 viruses, maintained at room temperature 
and tested by plaque assay at intervals up to 42 days. 
 
Direct Inoculation of Control Animals 
For both experiments, groups of each of the animals in the barnyard except 
ducks were housed in cages in a separate room and directly inoculated with virus to 
determine the effects of known exposure.  Chickens, pigeons, blackbirds and rats were 
inoculated intranasally with 10
6
 PFU in 0.1 ml.  Once daily on days 0-7, oropharyngeal 
and cloacal swabs were collected from the birds, and oral swabs from rats; these 
samples were processed as described above for duck samples.  Sera were collected on 
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days 0, 14, 21, and 28, and tested for anti-influenza antibodies by ELISA and for 
challenge virus-specific antibodies by HAI 
 
In vitro detection of persistence of virus 
Water was collected from a pool that had non-infected ducks swimming in it for 
24 hours prior to water collection.  This was done to mimic the natural state of the water 
from the barnyard study where water would also contain feces and food particles.  Pool 
water was then placed in a 50 ml conical tube and spiked with either 1x10
6
 PFU/ml of 
H5N2 or H7N3 virus and placed at room temperature.  A tube of the same water not 
spiked with virus served as the negative control and was collected and tested for virus.  
Samples were collected once daily on days 0 through 7 then weekly for 6 weeks.  One 
ml aliquots were collected at each time point and stored at -80 until all samples were 
collected.  Samples were then tested for virus titer utilizing the plaque assay. 
 
Results 
Clinical signs of disease were not observed in any of the birds or rats in the 
barnyard environments nor among those caged and directly inoculated with either virus.  
Animals in the barnyard were observed several times daily.  The ducks and chickens 
tended to cluster and move about in their own groups.  Blackbirds and pigeons spent 
much of their time perched above the floor, but were frequently observed walking on the 
floor or perched on the side of the pool.  All of the birds and rats were observed drinking 
from the pool and eating out of common feed bowls on the floor.  The rats were almost 
never seen out of their houses during daylight, but were confirmed by video to be 
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exceptionally active in running around the room and through the pool of water during 
the dark (Figure 2.1B). 
 
Infection and Transmission: H5N2 virus 
Virus was shed by all 4 inoculated ducks and transmitted to all 4 contact ducks 
either through direct contact or environmental contamination of the floor and shared 
pool (Table 2.1).  As would be expected with LPAIV in ducks, virus was shed to higher 
titers by the cloacal versus oral routes.  Contact ducks did not begin shedding detectable 
virus until at least 1 day after inoculated ducks began shedding.  Detectable shedding of 
virus from ducks ended on day 5 post inoculation.  H5N2 virus was first detectable in 
sampled water on day 2 post inoculation and continued until day 7 which was the last 
day samples were collected before the pool was emptied completely and refilled (Figure 
2.2).  Titers of virus were comparable in all three samples on each day except the floor 
sample from day four was 100-fold greater than either the sediment or surface pool 
water sample, likely due to a concentration of feces in that area on that day.  In vitro 
testing of H5N2 virus stability in pool water demonstrated a steady decline in virus titer 

















Virus titer in swab sample (log10 PFU/ml) 
1§ 2 3 4 5 6 7 
H5N2 
Inoculated 
CLO 2 <1.0 <1.0 <1.0 1.0 2.0 <1.0 <1.0 
3 <1.0 4.7 2.8 1.5 <1.0 <1.0 <1.0 
4 <1.0 3.0 3.6 3.1 2.9 <1.0 <1.0 
6 <1.0 5.9 3.8 3.0 2.0 <1.0 <1.0 
OP 2 <1.0 1.3 <1.0 <1.0 <1.0 <1.0 <1.0 
3 2.3 1.3 <1.0 1.0 <1.0 <1.0 <1.0 
4 <1.0 <1.0 <1.0 2.0 <1.0 <1.0 <1.0 
6 <1.0 1.0 <1.0 1.0 <1.0 <1.0 <1.0 
Contact 
CLO 1 <1.0 <1.0 3.1 4.6 3.1 <1.0 <1.0 
5 <1.0 <1.0 4.6 3.3 2.7 <1.0 <1.0 
7 <1.0 <1.0 4.1 3.9 3.3 <1.0 <1.0 
8 <1.0 <1.0 3.0 4.3 2.9 <1.0 <1.0 
OP 1 <1.0 <1.0 <1.0 1.0 <1.0 <1.0 <1.0 
5 <1.0 <1.0 1.9 1.5 1.5 <1.0 <1.0 
7 <1.0 1.5 1.8 2.3 <1.0 <1.0 <1.0 
8 <1.0 <1.0 1.5 <1.0 1.8 <1.0 <1.0 
H7N3 
Inoculated 
CLO 1 <1.0 4.4 3.7 2.5 <1.0 <1.0 <1.0 
2 3.3 3.5 3.0 2.9 1.0 1.6 <1.0 
3 2.3 3.5 3.0 2.5 1.3 <1.0 <1.0 
7 <1.0 3.5 2.9 3.3 2.3 <1.0 <1.0 
OP 1 1.3 3.0 1.5 2.4 1.7 2.3 <1.0 
2 2.3 2.5 2.5 2.9 1.3 1.0 <1.0 
3 1.0 <1.0 1.0 3.3 1.0 <1.0 <1.0 
7 2.7 2.3 2.6 2.9 1.7 <1.0 <1.0 
Contact 
CLO 4 <1.0 2.6 3.6 3.3 <1.0 <1.0 <1.0 
5 <1.0 3.3 3.0 3.6 2.0 <1.0 1.0 
6 <1.0 4.6 3.7 2.0 3.7 1.0 <1.0 
8 <1.0 6.3 6.5 3.5 3.7 1.0 <1.0 
OP 4 <1.0 2.5 1.8 1.6 2.5 <1.0 <1.0 
5 <1.0 1.0 2.0 1.6 1.5 <1.0 <1.0 
6 <1.0 2.3 2.0 <1.0 1.3 <1.0 <1.0 
8 <1.0 2.0 2.3 2.3 2.9 <1.0 <1.0 
* Samples are cloacal (CLO) or Oropharyngeal (OP); § Numbers represent days post challenge 
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Figure 2.2.  Accumulation of H5N2 viruses in barnyard pool water.  Water samples 
skimmed from the surface of the pool, off the bottom (sediment-rich) or splashed onto 




Figure 2.3. Survival of H5N2 and H7N3 viruses added to duck pool water and 
maintained at ambient temperature.  Water from a pool used by non-infected ducks was 




In the experiment in which control animals were directly inoculated,  83% of 
chickens and 100% of blackbirds shed detectable virus orally on days 1 through 5 and 1 
through 6 respectively (Table 2.2).  Small amounts of virus were detected sporadically 
on cloacal swabs from 1 chicken on day 4.  Virus was not recovered from rats or 
pigeons that were directly inoculated with virus. 
 
Table 2.2. Virus isolation from oropharygeal swabs taken from directly inoculated 
control animals. 
 
Virus Species Number Shed Days shed Peak day of 
shedding 
Peak virus titer 
(log10 PFU/ml) 
(log10 
PFU/ml) H5N2 Chicken 5/6 1-5 3 2.6 
Blackbird 6/6 1-6 2 3.6 
Pigeon 0/6 NA NA NA 
Rat 0/6 NA NA NA 
H7N3 Chicken 5/6 1-7 2 2.3 
Blackbird 4/4 1-7 4 4.0 
Pigeon 1/6 1-3 1 3.5 
Rat 0/6 NA NA NA 
 
 
In order to determine infection rates of all animals exposed in the barnyard or 
those directly inoculated, sera were collected on days 0, 14, 21 and 28 post-inoculation 
or exposure.   
The contact chickens in the barnyard had seroconversion rates of 63% by HAI 
and 100% by ELISA (Table 2.3).  None of the barnyard contact rats and blackbirds 
seroconverted by either HAI or ELISA.  For the directly inoculated control animals, 
there was 100% seroconversion in the chickens and rats by both HAI and ELISA but 
only 50% (1/2) in the blackbirds by HAI (Table 2.3). The ELISA failed to detect 
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antibody in any blackbird, regardless of HAI titer or virus isolation.  One caveat to the 
experiment relevant to the blackbirds is that repeated daily handling to obtain the cloacal 
and oral swabs proved too stressful, and 3 of the 6 blackbirds died due to non-influenza 
complications before serum collection was initiated on day 7. 
 
Table 2.3. Seroconversion following virus exposure in directly-inoculated (caged) and 
contact (barnyard) animals. 
 
Species and exposure 
H5N2 virus H7N3 virus 
HAI* ELISA HAI ELISA 
Duck, Inoculated 3/4 (75%)§ 4/4 (100%) 1/4 (25%) 4/4 (100%) 
Duck, Contact 3/4 (75%) 4/4 (100%) 2/4 (50%) 4/4 (100%) 
Chicken, Inoculated 6/6  (100%) 6/6 (100%) 4/6 (67%) 6/6 (100%) 
Chicken, Contact 5/8 (63%) 8/8 (100%) 8/8 (100%) 8/8 (100%) 
Blackbird, Inoculated 1/2 (50%)* 0/2 (0%)* 1/1 (100%)* 0/1 (0%)* 
Blackbird, Contact 0/10 (0%) 0/10 (0%) 4/5 (80%) 0/5 (0%) 
Pigeon, Inoculated 0/6 (0%) 5/6 (83%) 0/6 (0%) 2/6 (33%) 
Pigeon, Contact ND ND 0/6 (0%) 5/6 (83%) 
Rat, Inoculated 6/6 (100%) 6/6 (100%) 4/5 (80%) 5/5 (100%) 
Rat, Contact 0/8 (0%) 0/8 (0%) 0/7 (0%) 6/7 (86%) 
*HAI titer > 10 were considered positive. 
§ Number of birds positive/total (% positive) at any one timepoint from days 14, 21, or 28 
 
Infection and Transmission: H7N3 Virus 
Virus was shed by all 4 inoculated ducks and transmitted to all 4 contact ducks 
(Table 2.1).  Virus was shed longer, and to slightly higher titers than with the H5N2 
virus isolate, which was only detectable to day 5.  Virus titers from oral samples were 
also higher than oral viral titers seen in the H5N2 experiment.  As seen with the H5N2 
experiment, contact ducks did not shed detectable virus until at least 1 day after 
inoculated ducks began shedding, as would be expected in cases of transmission (Table 
2.1).  Virus shedding was detected in at least 1 duck on all days 1 through 7.  For the 
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H7N3 experiment the number of days of water sample collection was extended from 7 
days to 9 before cleaning out the pool.  H7N3 virus was detected in samples from day 1 
through day 9, with floor samples showing the highest levels of virus at all time points. 
(Figure 2.4)  H7N3 virus was also tested in vitro for stability, and behaved similarly to 
the H5N2 virus with viable virus detected out to day 42 (Figure 2.3).  
 
 
Figure 2.4.  Presence of H7N3 viruses in barnyard pool water.  Water samples skimmed 
from the surface of the pool, off the bottom (sediment-rich) or splashed onto the floor 
were assayed for infectious virus by plaque assay on MDCK cells. 
 
Virus isolation was also performed on all control animals directly inoculated 
with H7N3 virus, including blackbirds, pigeons, chickens and rats.  Virus was isolated 
from oropharygeal swabs at various time points from 83% of chickens, 16% of pigeons, 
and 100% of blackbirds (Table 2.2), but was not isolated from any of the oral swabs 
collected from rats. 
Transmission rates in the barnyard were assessed serologically on days 0, 14, 21 
and 28 post inoculation.  Only 25% of virus-inoculated ducks seroconverted based on 
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HAI results but 100% were positive by ELISA, correlating with the fact that 100% shed 
virus to varying degrees in the experiment (Table 2.3).   Of the 4 contact ducks, 50% 
seroconverted by HAI and 100% by ELISA.  Also in the barnyard, contact chickens, 
rats, blackbirds, and pigeons seroconverted at 100%, 0%, 80%, and 0% respectively as 
detected by HAI, and 100%, 86%, 0%, and 83% by ELISA (Table 2.3). 
For the directly inoculated chickens, rats, blackbirds, and pigeons we observed 
seroconversion rates of 67%, 80%, 100%, and 0% by HAI respectively, and 100%, 
100%, 0%, and 33% by ELISA respectively (Table 2.3).  As with the H5N2, the 
experimentally infected blackbirds did not all survive to day 7 for serum collection, so 
the percentage represents only one of the original four blackbirds that survived to the 
end of day 21 (Table 2.3). 
Discussion 
In both barnyard experiments, introduction of recently-infected mallards was 
followed rapidly by infection and shedding of virus by contact ducks, and the presence 
of substantial quantities of virus in water from the shared pool.  Based on detection of 
seroconversion, ducks infected with either virus efficiently transmitted the virus  to 
other species either through direct contact, which would be most likely with the contact 
ducks, or through contamination of the environment such as the pool and floor water 
where high virus titers were recovered in titers high enough to infect the other species.  
The H7N3 virus was transmitted to a large fraction of other animals in the room, 
including blackbirds, pigeons and rats, but transmission of the H5N2 virus to blackbirds 
and rats was not detected.   This apparent difference in cross-species transmission may 
reflect, in part, differences in transmissibility between the two viruses, but it is more 
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likely that transmission of the H7 virus was enhanced due to its higher magnitude and 
duration of shedding, and higher levels of accumulation in the shared water source 
compared to that of the H5 virus.  As anticipated, neither of the two viruses induced 
noticeable signs of disease in any of the exposed animals, including those directly 
inoculated with virus. 
The high titers of virus that accumulated in water of the shared barnyard pools 
undoubtedly were in excess of what might typically be expected in natural situations 
involving wild mallards, but may not be altogether unrealistic for low pathogenic AIVs 
in small bodies of water.  Moreover, it seems likely that such titers may occur in ponds 
associated with high density domestic duck production facilities, although studies 
attempting to measure virus titers in such situations are lacking with ducks.  The 
presence of environmental AIV in water habitats of turkeys supports the need for 
increased environmental sampling along with avian surveillance studies (Sivanandan et 
al, 1991).  It is evident, however, from this and other experimental studies, that efficient 
transmission via contaminated water can occur among ducks and between ducks and 
other birds [Forrest et al, 2010, VanDalen et al, 2010). 
Rats were included in the barnyard transmission experiments because they or 
other rodents are inevitably present in variable numbers on small farms, are in direct 
contact with ducks and poultry and are able to move freely among enclosures.  Live 
markets in Asia, where H5N1 influenza is prevalent, are an additional setting where 
large numbers of rats live in close contact with ducks and chickens (Shortridge et al, 
1998). The role of rodents in facilitating spread of AIVs is essentially unknown.  Rats 
housed in the H7N3 contaminated barnyard room seroconverted to that virus, as did 
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caged rats inoculated with both H5N2 and H7N3 viruses.  Neither virus was shed from 
infected rats as measured in our study, supporting the idea that they do not play a 
significant role in transmission to other species.   
Sero-surveys in natural settings (Arenas et al, 1990, DeMarco et al, 2003, 
Niqueux et al, 2010) as well as in experimental studies (Fereidouni et al, 2010) have 
provided valuable insights into the infection rates of mallards and other wild birds.  In 
the current study, seroconversion was used to evaluate virus transmission among the 
barnyard animals and to assess infection in the animals directly inoculated with virus.  
Further, it would have been extremely stressful to capture the blackbirds and pigeons 
daily to obtain samples for virus isolation.  Results obtained from the nucleoprotein 
blocking ELISA more accurately reflected the results of virus isolation and known virus 
exposure than did the HAI test, and allowed detection of virus transmission to rats and 
pigeons in the H7 barnyard trial.  An interesting exception to this finding was that the 
ELISA consistently failed to detect antibodies to either influenza virus in blackbird sera 
despite positive findings by HAI testing.   Results reported here suggest that multiple 
serologic tests are necessary to accurately conduct serosurveillance for influenza viruses 
when diverse species are involved.   Additional research to identify factors responsible 
for these serologic discrepancies would clearly be beneficial to surveillance efforts and 
allow an enhanced understanding of the ecology and evolution of avian influenza 
viruses worldwide. 
 Both LPAIVs tested efficiently spread from ducks to chickens within the shared 
environment, and a majority of chickens directly inoculated with these viruses shed 
them at reasonable levels from the intestinal tract; we did not test whether chicken-to-
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chicken transmission occurred.  Transmission of LPAIV from ducks to chickens, if 
accompanied by mutations in the hemagglutinin gene encoding the HA-1:HA-2 
cleavage site, could lead to generation of a HPAIV and a subsequent outbreak in 
poultry.  It is not known whether either of these viruses replicating in chickens, 
blackbirds, or pigeons might evolve and adapt to those hosts, allowing the new host to 
better transmit the virus, or whether the virus would encounter a dead end in the new 
host. 
Small farms, live and wet markets and many poultry shows provide abundant 
opportunities for interactions among free ranging and domestic species which may result 
in transmission and perpetuation of AIVs, particularly when ducks are involved.  The 
studies reported here indicate that introduction of ducks infected with LPAIV into a 
room designed to mimic a typical barnyard resulted in efficient dissemination of virus to 
a number of other species, including other birds and rodents.   This model system should 
be extended to investigate more refined questions, such as transmission from passerines 
to ducks or chickens, multiround transmission and transmission involving additional 
viruses, including H5N1 AIV. 
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CHAPTER 3: THE EFFECT OF OSELTAMIVIR CARBOXYLATE 
CONSUMPTION ON THE EMERGENCE OF DRUG RESISTANT AVIAN 
INFLUENZA VIRUS IN DUCKS 
 
Summary 
Oseltamivir carboxylate (OC) has been detected in environmental waters at 
varying levels during typical flu seasons in humans, reflecting high level usage of this 
drug.  This prompted us to evaluate the effect of consumption of low doses of OC on 
development of oseltamivir-resistant mutants in mallard ducks (Anas platyrhynchos) 
infected with two different low pathogenic H5N2 influenza viruses.  We found that 
oseltamivir resistance did emerge repeatedly in OC-exposed mallards infected with 1 of 
the 2 strains of influenza virus, but not in ducks that were not exposed to the drug.  The 
E119V mutation that arose, conferring resistance to oseltamivir, was found to be stable in 
vitro and had similar replication kinetics when compared to wild-type, but was unstable 
in vivo in the absence of OC.  Only the wild-type parent strain 182742WT was 
transmitted to naïve ducks.  The ducks infected with 182742-MUT-E119V showed a 1 
day delay in shedding with only the wild-type virus being transmitted.  Sequencing of 
isolates recovered from both inoculated and contact naïve ducks detected only the wild-
type strain present in all ducks, indicating the instability of this E119V mutation in 
mallards.  These results show the differing capabilities of the E119V mutation to replicate 
and transmit as efficiently as wild-type between mammals, humans, and water fowl. 
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Introduction 
Oseltamivir is one of the most widely prescribed antiviral drugs in the world and 
is used primarily for treatment of human influenza virus infections.   This antiviral is 
administered orally as oseltamivir phosphate (OP), which is readily absorbed and has 
high oral bioavailability.  In humans, OP is metabolized in the liver to the active 
metabolite oseltamivir carboxylate (OC), which is not metabolized further and is excreted 
primarily in urine (He et al, 1999), leading to large quantities of the drug entering 
wastewater when drug usage in the population is high.  Importantly, OC is poorly 
removed or degraded by natural environmental conditions or sewage treatment (Singer et 
al, 2007, Bartels and von Tumpling jr, 2008, Fick et al, 2007, Straub 2009, Hutchinson et 
al, 2009), resulting in significant retention in waterways.  These same waterways often 
support large numbers of waterfowl, the primary reservoir of avian influenza A viruses 
(AIV), and waterfowl in several parts of the world are likely exposed over lengthy 
periods to at least low doses of OC in their drinking water.  In contrast to mammals, 
AIVs replicate predominantly in the intestinal tract of ducks and other waterfowl, and 
there is reason for concern that the presence of OC in the intestinal lumen may promote 
selection of AIVs that are resistant to oseltamivir. 
In order to obtain a better understanding of the risk for emergence of resistance to 
oseltamivir due to environmental contamination with the drug, we infected mallard ducks 
with two different low pathogenic avian influenza (LPAI) H5N2 strains of mallard virus, 
while giving them access to drinking water containing low doses of OC.  We used a 
concentration of OC that approximated concentrations that have been found naturally in 
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water. Furthermore, if resistance was detected, we hypothesized that the oseltamivir 
resistant virus would be as transmissible as the wild type progenitor. 
 
Materials and Methods 
Ethics Statement 
All experiments were approved by the Institutional Animal Care and Use 
Committee of Colorado State University, Fort Collins, Colorado, USA, under approval 
number 09-168A. 
Animals 
Mallard ducks were purchased as hatchlings from either Stromberg‟s Chicks and 
Gamebirds Unlimited (Pine River, MN) or Murray McMurray Hatchery (Webster City, 
IA).  Ducklings were housed in an ABSL3 facility until four to six weeks of age at the 
start of each experiment.  All ducks tested negative by ELISA for group specific 
antibodies to an influenza type A virus antigen (recombinant nucleoprotein), (Flu 
DETECT BE, Synbiotics Corporation, Kansas City, MO) and strain specific antibodies to 
H5N2 by hemagglutination inhibition (HAI) assay prior to infection. 
 
Viruses and Chemicals 
The viruses used in this study were A/mallard/Minnesota/346250/00 (H5N2) and 
A/mallard/Minnesota/182742/98 (H5N2).  Both viruses were propagated by passage in 
10 day old specific pathogen free embryonated chicken eggs (Sunrise Farms, NY).  Eggs 
were incubated at 37º C and allantoic fluid was harvested 48-72 hours after inoculation, 
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aliquoted, and stored at -80º C until use.  Both viruses were titrated by plaque assay on 
MDCK cells and titers expressed as plaque-forming units (PFU)/ml. 
Viruses utilized in the neuraminidase inhibition assay (NAI) were obtained from 
the Centers for Disease Control, Atlanta, GA, grown once in MDCK cells, and used as 
the sensitive and resistant controls.  The virus strains used included A/Texas/36/1991 
(H1N1) and its H274Y resistant strain, and A/Wuhan/395/95-like (H3N2) and it‟s E119V 
resistant strain. 
Viruses used in the transmission study included the previously mentioned stock of 
A/mallard/Minnesota/182742/98 (H5N2) and its resistant counterpart 182742-MUT-
E119V that was recovered from a duck cloacal swab as a picked plaque, grown up in 
eggs, and passaged one additional time in eggs to obtain a stock virus.  All viruses were 
sequenced prior to infection of ducks to verify the presence or absence of the E119V 
mutation. 
Oseltamivir phosphate (Ro-64-0796) and oseltamivir carboxylate (Ro-64-0802) 
were provided by F. Hoffman-La Roche (Roche Diagnostics GmbH, Mannheim, 
Germany) and were utilized in both the NAI assays and mallard exposure studies. 
 
Plaque Assay 
The plaque assay was performed as previously described (Achenbach and Bowen, 
2010).  Plaques were either visualized with an overlay containing neutral red or with 
crystal violet staining.  Briefly, for crystal violet staining, 48-72 hours after cells were 
inoculated, the primary overlay was removed, and cells were fixed with 70% ethanol for 
 95 
30 minutes, followed with staining with 1% crystal violet for 15 minutes.  Plates were 
rinsed with tap water and allowed to air dry before counting plaques. 
 
Replication Kinetics 
Single-step and multistep growth curves were determined for both the 182742WT 
and 182742-MUT-E119V viruses in MDCK cells.  Cells were grown in 6-well tissue 
culture plates until ~90-95% confluency.  Based on cell count, the cells were infected at a 
multiplicity of infection (MOI) of 2 PFU/cell for the single-step growth curve and an 
MOI of 0.01 PFU/cell for the multistep growth curve.  Following one hour incubation at 
37° C and 5% CO2, cells were rinsed two times with PBS and overlayed with DMEM 
supplemented with antibiotics, 0.5% bovine serum albumin (BSA) and 1µg/ml of TPCK 
trypsin.   Supernatants were collected at 2, 4, 6, 8, and 10 hours post-infection for the 
single-step growth curve and at 12, 24, 36, 48, 60, and 72 hours post-infection for the 
multistep curve, both in duplicate, and stored at -80° C until titrated by plaque assay. 
 
Detection of Oseltamivir-Resistant Viruses from Ducks 
The inhibition of viral neuraminidase (NA) by oseltamivir was analyzed using the 
NA-Star® influenza neuraminidase inhibitor resistance detection kit (NAI, Applied-
Biosystems, Foster City, CA) according to the manufacturer‟s protocol.  Initially, duck 
cloacal swabs were diluted in 10-fold dilutions for the plaque assay, and 50 individual 
plaques were picked for each duck from virus shed at the latest possible time point.  
Virus from each plaque was inoculated into eggs to obtain stock viruses.  The egg grown 
samples were tested in the NAI assay.  Virus samples were diluted at least 5-fold to 
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obtain a signal to noise ratio of 10:1 to 60:1.  Luminescence was measured using the 
Victor™ X5 Multilabel Plate Reader (Perkin-Elmer, Waltham, Massachusetts) equipped 
with automatic injectors for the addition of NA-Star Accelerator.  IC50s were determined 
using the JASPR v1.1 (beta) software for curve fitting and analysis, provided by the 
Virus Surveillance and Diagnosis Branch at the Centers for Disease Control, Atlanta, 
GA.  Statistical analysis of IC50s from picked plaques followed the outline described by 
Sheu et al (2008), which required an IC50 ± 3SD as a cutoff for outliers of resistance to 
minimize the number of samples tested by sequencing.  This proved to be acceptable 
when compared to final sequencing results which confirmed resistance. 
 
RT-PCR and Sequencing of the Neuraminidase Gene 
RNA was extracted from either allantoic fluid or directly from duck cloacal swabs 
using TRI Reagent® (Molecular Research Center, Inc, Cincinnati, OH) according to 
manufacturer‟s directions.  Both amplification of PCR product and sequencing of the NA 
N2 gene utilized primers based on Chander et al (2010) and named NA-2.1, NA-2.3, NA-
2.5, NA-2.6 (forward and reverse).  We also designed one additional primer 1413R (5´-
ATA GGC ATG AAG TTG ATA TTC GC-3´) to amplify the entire NA gene from the 3′ 
end.  RT-PCR was performed using a one step RT-PCR kit (Qiagen, Valencia, CA) 
according to the manufacturer‟s protocol.  Amplification involved an initial RT step of 
50° C for 30 minutes, followed by heating at 95° C for 15 minutes, 3-step cycling of 35-
40 cycles with denaturation at 95° C for 1 min, followed with annealing at 53° C for 1 
minute, and extension at 72° C for 1 min, with one final extension of 72° C for 10 
minutes.  For sequencing, PCR amplicons were electrophoresed in a 1-2% agarose gel 
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and DNA was extracted using the QIAquick® gel extraction kit (Qiagen, Valencia, CA) 
according to manufacturer‟s directions.  PCR fragments were sent to the Proteomics and 
Metabolomics Facility at Colorado State University, Fort Collins, CO.   Sequencing was 
done in both directions utilizing the same primers described above.  Sequences were 
aligned and analyzed using the MEGA 5 software (Tamura et al, 2011). 
Site specific RT-PCR to Differentiate Wild-type from Mutant Viruses 
RNA was extracted as previously described and was subjected to RT-PCR 
utilizing a specific set of primers designed to detect the specific point mutation of 
nucleotide 356 A to T which changes the amino acid glutamic acid to valine (E119V) 
(Table 3.1).  The same forward primer was used in both RT-PCR assays with two 
different reverse primers to differentiate between the wild-type and mutant viruses.  The 
mutant reverse primer had the specific point mutation on the 3′ end as well as an 
additional point mutation 3 base pairs from the terminus on the 3′ end.  This additional 
mismatch allowed for a destabilization of the primer to minimize anomalous products 
from forming (Newton et al, 1989, Latorra et al, 2003, Renaud et al, 2010).  The RT-PCR 
cycling parameters are the same as above with the annealing temperature raised to 61º C 
to differentiate between wild-type and mutant using the wild-type primers.  The 
annealing temperature of 53º C was used with mutant primers. 
 
Table 3.1. Primer sequences for site-specific RT-PCR 
 
 Forward primer Reverse Primer 
182742WT_E119 5′-GCAGATTGCCATCCTAGC -3′ 5′-GGTGTCACATGACACATAAGGTT-3′ 
182742MUT_E119V 5′-GCAGATTGCCATCCTAGC -3′ 5′-GGTGTCACATGACACATAAGaTA-3′ 
- Nucleotide in red is the specific point mutation change, and the nucleotide in red 
lowercase is the intentional mismatch 
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Pharmacokinetics of Oseltamivir in Mallards 
Six juvenile mallard ducks were gavaged with 5mg of oseltamivir phosphate 
(Tamiflu, Ro 64-0796) dissolved in 2.5ml sterile water.  Approximately 1 ml of blood 
was collected in lithium-heparin tubes from each duck at pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 
12, 24, and 48 hours post-dose.  Blood samples were centrifuged and plasma was 
collected and stored at -80º C until assayed by PRA International (Assen, the 
Netherlands).  Samples were extracted using a C18 solid phase extraction method and 
analysis was performed utilizing LC-MS/MS tandem mass spectrometry.  Internal 
standards included deuterated oseltamivir and oseltamivir carboxylate (Ro 64-0802). 
 
Pharmacokinetic Statistics 
The plasma concentrations of OP and OC were supplied by Dr. Nicolas Abello of 
PRA International to Roche Pharmaceuticals (Nutley, NJ), who performed all of the 
pharmakokinetic stastical analyses and provided us with the final data.  The final data 
was kindly summarized by Clinical Pharmacologist, Dr. James R. Smith, Roche.  
Noncompartmental pharmacokinetic parameters were calculated using WinNonlin 
Enterprise, version 5.2.1 (Pharsight Corporation, St. Louis, MO).  The values of the 
maximum plasma concentration (Cmax) and time to Cmax (Tmax) for each duck were the 
observed values. The area under the plasma concentration time curve was determined 
using the linear trapezoidal method for the time periods of 0 to 12 h post-dose (AUC0-12h) 
and from 0 to the last measurable plasma concentration (AUC0-t). The area under the 
curve from the last measurable concentration (Ct) to infinity was calculated as Ct/λz, 
where λz is the elimination rate constant, which was calculated using at least 3 time points 
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of the log linear portion of the elimination curve. AUC from 0 to infinity (AUC0-∞) was 
calculated as AUC0-t + Ct/λz. The elimination half-life was calculated as ln 2/ λz.  Oral 
clearance (CL/F) was determined as the dose divided by AUC0-∞ and the oral volume of 
distribution (Vz/F) was calculated as dose/(AUC0-∞ x λz).  CL/F and Vz/F were divided 
by the weights of ducks to facilitate comparison to human data. 
 
Oseltamivir Carboxylate Treatment of Mallards and AIV Infection 
These studies were designed to simulate exposure of ducks to low levels of OC in 
drinking water prior to infection with AIV.  Four separate groups of mallard ducks aged 
4-6 weeks were divided into separate rooms as outlined in Table 3.2, based on the 
concentration of drug provided in water and were allowed to free range within a 12 foot x 
18 foot sized room. Groups of mallards given OC in their drinking water were started on 
drug 24-48 hours before challenge while control ducks were supplied water with no OC.  
The concentration of OC in water ranged between 10 and 10,000 ng/L.   
 
Table 3.2.     OC in the mallard model experimental groups 
Group 
Virus inoculum* 
           1                      2          3                         4 
346250 182742 182742 346250 
10,000ng/L OC 2 ducks 2 ducks   
1,000ng/L OC 2 ducks 2 ducks   
100ng/L OC 2 ducks 2 ducks 4 ducks 5 ducks 
10ng/L OC 2 ducks    
No OC 2 ducks 2 ducks 4 ducks 5 ducks 
* A/Mal/MN/346250/00 (346250), A/Mal/MN/182742/98 (182742) 
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All water dishes were re-filled daily at the time of cloacal swab collection.  All ducks 
were inoculated on day 0 with 10
6
 PFU of either H5N2 virus orally and intranasally in the 
first two groups and through their choanal cleft in groups 3 and 4.  The change in 
inoculation route to the choanal cleft was done to facilitate a more natural inoculation 
route which led to increased consistency of infection and shedding by mallards.  Cloacal 
swabs were collected daily in 2ml BA-1 medium (MEM, 1% BSA, 350 mg/L sodium 
bicarbonate, 50ml/L 1M Tris, pH7.6, 5mg/L phenol red) supplemented with antibiotics 
(gentamicin 50 ug/ml, polymyxin B 100 U/ml, nyastatin 50 U/ml, penicillin, 100 U/ml 
and streptomycin 50 ug/ml) from days 0 through days 7 or 10.  Swab samples were split 
into duplicate 1ml volumes and stored at -80° C until tested by plaque assay.  In the first 
two groups (group 1 and 2), cloacal swabs were tested for viral titer by plaque assay, and 
individual plaques were picked, grown once in eggs, and tested in the NAI assay for drug 
resistance.  Any sample that had an increased IC50 was then sequenced by the traditional 
Sanger sequencing method.  For the last two groups (group 3 and 4), Sanger sequencing 
was performed on RNA extracted directly from cloacal swabs.  The direct sequencing 
from cloacal swabs was performed to help eliminate the possibility that the growth of 
picked plaques in eggs contributed to the emergence of resistance. 
 
Oseltamivir Phosphate Treatment of Mallards and AIV Infection 
This experiment was designed to mimic treatment of ducks with a single dose of 
OP shortly after exposure to AIV, a practice discussed to treat ducks in live markets 
where AIV infection frequently occurs.  Nine 5 week old mallard ducks were inoculated 
with 10
6
 PFU of 182742WT virus via the choanal cleft. Six hours post inoculation, 4 
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inoculated ducks were gavaged with 5mg oseltamivir diluted in 2.5ml distilled water, 
with the other 5 inoculated ducks getting 2.5ml of distilled water.  Cloacal swabs were 
collected on days 0 through day 7 and stored at -80° C until tested by plaque assay. 
 
Transmissibility of Mutant AIV in the Mallards   
To evaluate differences in direct contact or environmental contamination 
transmissibility of wild-type versus drug resistant AIV, we infected 5 week-old mallards 
with each virus, exposed them to non-infected ducks and monitored the rate of infection 
in the exposed ducks.  Two ducks from group 1 were inoculated with 10
6
 PFU of 
182742WT virus and 2 hours later, those inoculated ducks were introduced to mingle 
freely with 6 naïve ducks.  Similarly, two ducks from group 2 were inoculated with 10
6
 
PFU of 182742-MUT-E119V virus, 2 hours later they were then introduced to 6 naïve 
ducks.  Group 3 was divided into 3 groups of 4 ducks.  One duck in each group of 4 was 
inoculated with a mixture containing 10
6
 PFU of 182742WT virus and 10
6
 PFU of 
182742-MUT-E119V virus, then introduced 2 hours later to the other three naïve ducks 
in that group.  Blood was collected from all ducks prior to day 0 and again at day 14 to 
detect seroconversion utilizing the cELISA test.  Cloacal swabs were collected as 
previously described from days 0 through day 14 from all 28 ducks.  Cloacal swabs were 
divided into two separate 1 ml aliquots and stored at -80° C until testing for viral titer by 







Pharmacokinetics of Oseltamivir in Mallards 
Mean values of the plasma concentrations of OP and OC following oral dosing of 
ducks with OP are listed in Table 3.3, and the pharmacokinetic parameters are listed in 
Table 3.4.  Plasma concentrations of oseltamivir were detectable at 48 h post-dose while 
the carboxylate metabolite was detectable only to 24 h (Table 3.3).  The ratio of OC 
metabolite to parent OP concentrations was maximal at 0.5 h and declined from 0.908 to 
0.049 at 24 h.  Based on the values of AUC0-∞, the ratio of metabolite to parent was 0.16 
± 011. In duck 3, the concentration of the metabolite was greater than the parent in the 
first 4 samples for up to 2 hours, following a more human-like pattern.  The other 5 ducks 
had consistently higher concentrations of parent than metabolite.  
 
Table 3.3.     Mean (SD) Plasma Concentrations of Oseltamivir and Oseltamivir 
Carboxylate in Mallard Ducks Administered a Single Oral Dose of  
5 mg Oseltamivir Phosphate 
Hour Oseltamivir Oseltamivir Carboxylate Carboxylate/Oseltamivir Ratio 
0.25 1170 (585) 441 (200) 0.578 (0.587) 
0.5 886 (463) 481 (174) 0.908 (1.02) 
1 770 (405) 320 (134) 0.745 (0.948) 
2 637 (347) 165 (68.4) 0.415 (0.454) 
3 552 (273) 89.4 (39.0) 0.236 (0.209) 
4 459 (217) 64.0 (29.5) 0.195 (0.155) 
6 383 (180) 46.4 (19.3) 0.170 (0.122) 
12 292 (99.2) 24.3 (13.5) 0.105 (0.713) 
24 166 (72.3) 4.83 (7.90) 0.049 (0.085) 
48 26.5 (18.9) 0.00 (0.00) 0.00 (0.00) 
N = 6 
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Table 3.4.     Mean (SD) Pharmacokinetic Parameters of Oseltamivir and Oseltamivir      
Carboxylate in Mallard Ducks Administered a Single Oral Dose of  
5 mg Oseltamivir Phosphate 
Parameter (units) Oseltamivir Oseltamivir Carboxylate 
Cmax (ng/mL) 1190 (575) 487 (188) 
Tmax (h) 0.54 (0.71) 0.46 (0.10) 
AUC0-12h (ng·h/mL) 5490 (2500) 1140 (382) 
AUC0-t (ng·h/mL) 10500 (4030) 1240 (528) 
AUC0-∞ (ng·h/mL) 11000 (4240) 1390 (548) 
AUC0-∞ (ng·h/mL/mg) 2200 (847) 303 (119) 
t½ (h) 10.5 (3.00) 6.48 (1.61) 
CL/F (L/h) 0.517 (0.206) NC 
CL/F (L/h/kg) 0.468 (0.191) NC 
Vz/F (L) 7.67 (3.60) NC 
Vz/F (L/kg) 6.81 (2.91) NC 
N = 6 
NC = Not calculated  
The mean Cmax values for OP and OC were 1190 and 487 ng/mL, respectively 
(Table 3.4).  Tmax was approximately 0.5 h for both the parent and metabolite.  The mean 
t½ for OP was 10.5 h, which was longer than that for OC, which was 6.48 h.  CL/F of 
oseltamivir was 0.468 L/h/kg and Vz/F was 6.81 L/kg.  Comparisons of duck PK 
parameters and human parameters are outlined in Table 5.  There are some distinct 
differences between ducks and humans.  In humans, their exposure to OC as determined 
by AUC0-∞ is 22 times greater than exposure to OP, showing more efficient liver 
conversion to the active metabolite OC, which will interfere with NA in humans.  In 
ducks, the ratio is only 0.16, suggesting the possibility of conversion to OC in the gut 
lumen, where it is likely to directly interact with virus replication in the gut of the duck 
playing a more direct role.  Also, OP has a longer half-life in ducks compared to humans, 
but OC has a similar half-life in both species, suggesting they may share the same 
mechanism of clearance. 
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Table 3.5.     Comparison of Mean Pharmacokinetic Parameters of Oseltamivir and 
Oseltamivir Carboxylate in Mallard Ducks and Humans Following a Single 
Oral Dose of Oseltamivir 
Parameter (unit) 






Cmax (ng/mL) 1190 84 487 215 
Tmax (h) 0.54 1.00 0.46 5.00 
AUC0-∞ (ng·h/mL/mg) 2200 1.87 303 40.8 
t½ (h) 10.5 1.70 6.48 7.7 
CL/F (L/h/kg) 0.47 7.1 NC NC 
Vz/F (L/kg) 6.81 17.6 NC NC 
a:  Dose = 5 mg p.o. 
b:  Dose = 75 mg p.o.; mean wt = 75 kg; PK parameters from Clinical Study WP20727 
NC = Not calculated 
OC Treatment of Mallards and AIV Infection 
Two strategies were used in an attempt to minimize the number of viruses tested 
in evaluating the shedding of oseltamivir-resistant virus from ducks treated with OC in 
drinking water.  First, we tested viruses shed only from ducks receiving the highest dose 
of OC that did not completely inhibit virus shedding.  Second, initial testing was 
restricted to viruses isolated toward the end of the shedding period, assuming that if 
resistant viruses evolved, they would be present at the highest frequency at that time due 
to the selective pressure of continued presence of OC. 
Regarding the first group involving ducks administered OC in their drinking 
water and inoculated with A/mallard/MN/346250/00 virus, none of the shed viruses 
tested showed an increased IC50.  All samples were compared to control sensitive and 
resistant viruses in the NAI assay, and none of the picked plaques viruses from 
challenged ducks receiving OC or no OC showed an increased IC50.  Interestingly, 
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mallards that received 10,000 ng/L of OC in their drinking water failed to shed detectable 
virus on any day (Table 3.6). 
Table 3.6. Group 1, 10 individual ducks receiving differing concentrations of OC or no 
OC in their drinking water, and inoculated with A/Mal/MN/346250/00 (H5N2) with viral 




D1* D2 D3 D4 D5 D6 D7 
1 10000ng/L 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 10000ng/L 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 1000ng/L 0.00 3.30 4.43 4.30 0.00 0.00 0.00 
4 1000ng/L 0.00 2.60 4.36 2.00 0.00 0.00 0.00 
5 100ng/L 0.00 0.00 4.58 2.00 0.00 0.00 0.00 
6 100ng/L 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
7 10ng/L 0.00 0.00 0.00 3.78 0.00 0.00 0.00 
8 10ng/L 0.00 0.00 4.78 4.40 0.00 0.00 0.00 
9 No OC 4.00 3.95 4.48 3.30 0.00 0.00 0.00 
10 No OC 0.00 0.00 4.88 2.85 0.00 0.00 0.00 
*Days post inoculation 
Titers of virus shed from the second group of ducks that received varying 
concentrations of OC in water followed by inoculation with A/mallard/MN/182742/98 
virus are presented in Table 3.7.  In these ducks, increased IC50s were detected in 35 
picked plaques, from days 5 and 6, of 1 (duck 3) of 2 ducks receiving 1,000ng/L OC in 
drinking water.  None of 20 plaques picked from the sample collected from duck 3 on 
day 3 had an elevated IC50.  We utilized the method from Sheu et al, 2008 that was 
designed to minimize testing outliers and followed a cutoff of the mean IC50 + 3SD for 
which the 182742WT virus was 5.46nm.  The mean IC50 for plaques from duck 3 were 
17.43 ± 4.85 nM which was an 8.8 fold increase over the IC50 for the WT strain.  The 
individual plaques that had a > 5.46nm fold increase were subjected to Sanger sequencing 
which confirmed an A to T nucleotide change at position 356 which causes the amino 
acid (aa) to switch from glutamic acid (E) to valine (V) at position 119 (H3 numbering) 
mutation in the NA sequence.  There was also a mutation from A to G at nucleotide 
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position 510, but this did not affect the aa sequence.  Five different plaques from duck 3 
on day 3 were also sequenced, and no mutation was detected.  We also evaluated a set of 
serial NA sequences from duck 3 from RNA extracted from cloacal swabs for days 2, 3, 
4, 5, and 6 to determine which day post-inoculation the mutation is first detected.  The A 
to T mutation was first detected at day 5 as a mixed A/T population, with the T mutation 
becoming the dominant nucleotide on day 6.  This matches the results from the NAI 
assay that showed no increase in IC50 on day 3 but did detect an increase in IC50 on day 5.  
These results are also consistent with the A/Wuhan/395/95-like (H3N2) sensitive to 
resistant (E119V) control that also shows an 8-fold increase from sensitive to resistant 
change (Table 3.8).  No increased IC50s were seen in the 2 ducks getting no OC and 
challenge only.  Ducks that received 10,000ng/L OC in their drinking water did not shed 
detectable virus on any days post challenge.  This concentration appears to cut off 
detectable replication in the ducks, which is consistent with the IC50 determined from the 
mutant virus. 
 
Table 3.7. Group 2, 8 individual ducks receiving differing concentrations of OC or no 
OC in their drinking water, and inoculated with A/Mal/MN/182742/98 (H5N2) with viral 




D1* D2 D3 D4 D5 D6 D7 
1 10000ng/L 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 10000ng/L 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 1000ng/L 0.00 3.00 7.08 4.00 3.48 3.00 1.60 
4 1000ng/L 0.00 3.30 0.00 3.40 4.00 2.30 0.00 
5 100ng/L 0.00 2.78 0.00 0.00 0.00 0.00 0.00 
6 100ng/L 0.00 2.70 1.00 2.70 3.48 0.00 0.00 
7 No OC 0.00 3.78 3.70 0.00 0.00 0.00 0.00 
8 No OC 0.00 3.30 0.00 0.00 0.00 1.00 0.00 
*Days post inoculation 
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Table 3.8.     IC50 comparisons between control sensitive and resistant strains and 
182742WT and 182742-MUT-E119V. 
Virus strain Virus NA type NA mutation Mean IC50±SD(nm)(fold inc) 
A/TX/36/91 A/N1  3.20 ± 1.01 
A/TX/36/91 mut A/N1 H274Y 262.3 ± 204.4 (81.96) 
A/Wuhan/395/95-like A/N2  3.215 ± 0.73 
A/Wuhan/395/95-like 
mut 
A/N2 E119V 26.25 ± 4.25 (8.16) 
A/Mal/182742/98 A/mal/N2  1.97 ± 1.16 
A/Mal/182742/98 mut A/mal/N2 E119V 17.43 ± 4.85 (8.84) 
 
Group 3 was a partial replicate of study group 2 in which 4 ducks received 
1,000ng/L OC in their drinking water and 4 control ducks received no drug, with all 8 
ducks being inoculated via the choanal cleft with the 182742 virus.  This change in 
inoculation route shows a much better consistency of infection and viral shedding 
between ducks receiving drug or no drug as compared to groups 1 and 2.  We did not 
repeat the 10,000ng/L due to lack of viral replication in the previous two experiments.  
Viral titers were determined by plaque assay on MDCK cells (Table 3.9) and RNA was 
extracted directly from original cloacal swabs on the latest time point that virus was 
detected by plaque assay.  RNA was used in an RT-PCR reaction followed by Sanger 
sequencing of the NA gene.  Three of 4 ducks who received OC in their drinking water 
showed an amino acid change of E119V mutation in the NA gene, along with one other 
nucleotide change of A to G at position 510 that caused no amino acid change.  This is 
consistent with the results from group 2 that were inoculated with the same 182742 virus. 
Group 4 was a replicate experiment for group 1 which included 5 ducks getting 
1,000ng/L OC in their drinking water and 5 ducks getting no OC in their drinking water. 
All 10 were inoculated with the 346250 virus via the choanal cleft.  Viral titers were 
determined by plaque assay (Table 3.10) and RNA was extracted from cloacal swabs and 
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subjected to RT-PCR and Sanger sequencing.  None of the samples tested from the 10 
ducks showed nucleotide or amino acid changes in the NA gene sequence. 
 
Table 3.9. Group 3, 8 individual ducks were given either 1000ng/L (4 ducks) of OC or 
no OC (4 ducks) followed by inoculation with A/Mal/MN/182742/98 (H5N2) with viral 




D1* D2 D3 D4 D5 D6 D7 D8 D9 
1 1000ng/L 0.00 0.00 4.37 3.78 4.36 3.88 4.48 3.08 2.00 
2 1000ng/L 0.00 0.00 4.90 3.11 2.70 3.18 1.78 1.85 1.48 
3 1000ng/L 0.00 0.00 4.18 3.90 4.30 4.67 2.30 2.00 2.00 
4 1000ng/L 0.00 5.24 6.08 5.29 6.26 0.00 2.00 2.60 0.00 
5 no OC 0.00 5.71 3.68 4.30 4.70 3.04 0.00 0.00 0.00 
6 no OC 0.00 6.76 4.53 3.78 2.95 1.78 0.00 0.00 0.00 
7 no OC 0.00 0.00 2.95 5.22 2.40 2.60 3.85 0.00 0.00 
8 no OC 0.00 8.40 6.20 4.18 2.23 3.11 0.00 0.00 0.00 
*Days post inoculation 
 
Table 3.10. Group 4, 10 ducks receiving 1000ng/L of OC (5 ducks) or no OC (5 ducks) 
followed by inoculation with A/Mal/MN/346250/00 (H5N2) with viral titers represented 




D1* D2 D3 D4 D5 D6 D7 D8 D9 
1 1000ng/L 0.00 4.48 3.48 6.00 3.60 2.60 2.48 0.00 0.00 
2 1000ng/L 1.30 3.78 3.48 4.30 3.18 2.30 2.30 2.95 2.30 
3 1000ng/L 0.00 3.20 3.78 3.48 2.48 0.00 0.00 0.00 0.00 
4 1000ng/L 0.00 0.00 2.78 3.79 4.03 1.95 3.00 0.00 0.00 
5 1000ng/L 0.00 3.30 2.60 5.00 4.02 2.04 0.00 1.95 0.00 
6 no OC 4.30 5.15 4.85 3.30 0.00 0.00 0.00 0.00 0.00 
7 no OC 6.90 4.30 3.70 3.30 0.00 0.00 1.00 0.00 0.00 
8 no OC 4.40 3.70 4.30 2.85 2.70 0.00 0.00 0.00 0.00 
9 no OC 0.00 5.30 4.95 3.59 4.08 2.78 0.00 0.00 0.00 
10 no OC 0.00 3.95 4.48 2.76 0.00 3.48 0.00 0.00 0.00 




Effect of a Single Dose of Oseltamivir Phosphate in Mallards 
Administration of a single dose of OP shortly after challenge of mallards with the 
182742 virus resulted in significant suppression of virus replication in the host.  Four of 
the 5 ducks that received a single dose of OP did not shed any detectable virus on any 
days 0 through day 7 (Table 3.11).  One duck did shed virus on days 6 and 7 post 
challenge and drug treatment (Table 3.11).  RNA was extracted from cloacal swabs from 
this duck and was subjected to RT-PCR and Sanger sequencing.  Even though the plaque 
sizes were larger than the parental virus in the plaque assay, mutations in the NA gene 
were not detected by sequencing. 
 
Table 3.11. Nine individual ducks were challenged with A/Mal/MN/182742/98 followed 
with 4 ducks receiving a single 5 mg OP, and 5 ducks receiving a no OP (water only) 
dose with viral titers represented in log10 (PFU/ml). 
 
Ducks    D1* D2 D3 D4 D5 D6 D7 D8 
1 5mg OP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 5mg OP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3 5mg OP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4 5mg OP 0.00 0.00 0.00 0.00 0.00 2.30 3.85 0.00 
5 no OP 0.00 6.61 5.08 4.43 4.08 2.00 2.00 0.00 
6 no OP 0.00 4.08 3.95 0.00 2.18 2.30 0.00 0.00 
7 no OP 0.00 6.53 0.00 0.00 5.36 nt nt 0.00 
8 no OP 0.00 4.36 4.61 0.00 0.00 0.00 0.00 0.00 
9 no OP 0.00 4.69 4.04 4.20 3.15 2.48 2.00 0.00 
*Days post inoculation 
 
Replication Kinetics of Wild-Type and Resistant Virus 
We assayed the replication of both the 182742WT virus and 182742-MUT-
E119V virus, which is the plaque picked, egg grown isolate from duck 3, experiment 2, 
in both single-step and multistep growth curves in MDCK cells.  In both growth curves, 
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the MUT-E119V virus appeared to have a slight advantage over the growth of 
182742WT virus in vitro, reaching higher viral yields at 10 hours pi for the single-step 
growth curve and at all time points in the multistep growth curve, with a ≥ 1 log10 
difference over all time points except the 72 hour endpoint where the two titers were the 
same (Figures 3.1 and 3.2).  A comparison of the slopes of each virus growth curve over 
time was calculated utilizing linear regression ANOVA.  There were no statistical 
differences in slope between wild-type and mutant virus over time.   
 
 
Figure 3.1.  Single-step growth curve of 182742WT and 182742-MUT-E119V at an 




Figure 3.2. Multistep growth curve of 182742WT and 182742-MUT-E119V at an MOI 
of 0.01 PFU/cell 
 
 
Plaque size also increased from 1mm in diameter in the 182742WT to 3-5mm in 
diameter for the 182742-MUT-E119V (Figure 3.3).  While the increase in plaque size 
may play a role in the enzymatic activity of NA of the MUT-E119V virus it was not the 
only indication as mutations in the HA gene also need to be considered.  An occasional 
large plaque was detected in the 182742WT virus stock, but following sequencing of 
three large plaques picked from 182742WT virus, it was determined to be wild-type.  
This suggests that the increase in plaque size may play a role in vitro, but there are other 
factors to be considered, with the remaining 7 genes all working together, that are 






Figure 3.3. (A) 182743WT virus on MDCK cells, with plaque sizes of 1mm and (B) 
182742-MUT-E119V virus on MDCK cells, with plaque sizes of 3-5mm. 
 
 
Transmission of the E119V Mutant AIV in Mallards 
We evaluated both the replicative ability and the transmissibility of the 
182742WT virus, the 182742-MUT-E119V virus and a competitive 1:1 mixture of both 
viruses in mallard ducks.  With the 182742WT virus we saw good replication in the 2 
inoculated ducks at day 2 post-inoculation, and recorded detectable shedding on day 3 
from all 6 naïve contact ducks.  Viral shedding was detected through day 7 in three ducks 
with 1 duck still having detectable virus on day 8, the last day samples were collected 
(Table 3.12). 
Shedding was not detected in the 2 ducks inoculated with the 182742-MUT-
E119V virus until day 3, 1 day later than detectable shedding in ducks inoculated with 
182742WT virus.  The 6 naïve contact control ducks housed with inoculated ducks had 
detectable virus starting on day 4 and continuing through day 7, showing there was virus 
transmitted (Table 3.12). 
A B 
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Table 3.12.  Results of viral titers of all 28 ducks in the transmission experiment 
separated by type of inoculated virus, and group.  Ducks were either directly inoculated 
with virus or were contact naïve ducks placed in the same room as inoculated ducks. 
Viral titers are represented in log10 (PFU/ml). 
 
182742WT D1 D2 D3 D4 D5 D6 D7 D8 
Duck 1 inoculated 0.00 2.00 3.70 2.30 0.00 0.00 0.00 0.00 
Duck 2 inoculated 0.00 1.90 3.30 2.00 1.00 1.90 1.85 0.00 
Duck 3 naïve 0.00 0.00 3.75 3.30 4.04 0.00 2.60 0.00 
Duck 4 naïve 0.00 0.00 3.58 1.85 3.48 2.00 1.78 0.00 
Duck 5 naïve 0.00 0.00 5.15 0.00 0.00 1.70 0.00 0.00 
Duck 6 naïve 0.00 0.00 0.00 3.30 3.30 2.00 0.00 0.00 
Duck 7 naïve 0.00 0.00 4.78 2.90 3.18 0.00 0.00 2.30 
Duck 8 naïve 0.00 0.00 0.00 4.60 3.48 1.90 0.00 0.00 
182742-MUT-
E119V                 
Duck 9 inoculated 0.00 0.00 2.08 1.85 2.36 1.78 2.60 0.00 
Duck 10 inoculated 0.00 0.00 1.85 2.54 3.70 1.70 1.85 0.00 
Duck 11 naïve 0.00 0.00 0.00 1.60 2.18 3.70 3.30 0.00 
Duck 12 naïve 0.00 0.00 0.00 0.00 1.70 3.48 2.60 0.00 
Duck 13 naïve 0.00 0.00 0.00 1.78 2.00 3.48 2.30 0.00 
Duck 14 naïve 0.00 0.00 0.00 0.00 3.70 2.85 3.00 0.00 
Duck 15 naïve 0.00 0.00 0.00 3.30 2.04 1.78 0.00 0.00 
Duck 16 naïve 0.00 0.00 0.00 0.00 3.18 4.30 0.00 0.00 
1:1 mixture                 
Duck 17 inoculated 0.00 1.70 7.69 3.60 0.00 2.49 0.00 0.00 
Duck 18 naïve 0.00 0.00 0.00 3.18 2.23 3.30 2.60 0.00 
Duck 19 naïve 0.00 0.00 4.30 3.79 4.00 3.30 1.70 0.00 
Duck 20 naïve 0.00 0.00 0.00 3.30 3.48 3.90 2.60 0.00 
                  
Duck 21 inoculated 0.00 3.60 4.04 2.85 3.00 2.00 0.00 1.30 
Duck 22 naïve 0.00 0.00 4.08 3.30 2.36 3.78 0.00 0.00 
Duck 23 naïve 0.00 0.00 3.95 3.85 2.00 2.60 2.18 0.00 
Duck 24 naïve 0.00 0.00 3.70 3.78 3.30 0.00 0.00 0.00 
                  
Duck 25 inoculated 0.00 5.60 4.00 4.48 3.58 3.30 2.78 1.85 
Duck 26 naïve 0.00 0.00 0.00 4.34 3.00 2.08 2.70 0.00 
Duck 27 naïve 0.00 0.00 4.15 6.00 5.70 3.71 1.48 0.00 




For the 3 ducks inoculated with a 1:1 mixture of 182742WT and 182742-MUT-
E119V viruses, there was detectable shedding on day 2 that continued through day 7 in 
group 1, and through day 8 in groups 2 and 3 (Table 3.12).  Titers detected in both 
inoculated and contact naive ducks were analyzed utilizing ANOVA and comparing their 
area under the curve (AUC) values.  There were some statistically significant differences 
in viral titers between the 3 different groups.  Wild-type naïve ducks had significantly 
higher titers than mutant directly inoculated ducks (P = 0.02).  Mutant naïve ducks had 
higher titers than dual infected naïve ducks (P = 0.004).  Wild-type naïve ducks had 
higher titers than wild-type inoculated ducks (P = 0.04), than dual infected directly 
inoculated (P = 0.03), and dual infected naïve ducks (P<0.0001).   
RNA was extracted from cloacal swabs of ducks on the latest day of detectable 
shedding for all 28 ducks that were inoculated with virus or infected by bird-to-bird 
transmission.  Sanger sequencing was performed on RNA from all samples, and all 28 
samples had the E119 wild-type phenotype.  Earlier samples from the ducks that received 
182742-MUT-E119V samples were also subjected to Sanger sequencing and were 
determined to not contain the E119V mutation.  Based on the cELISA, all 28 ducks did 
seroconvert by day 14 detecting positive for antibody against avian influenza. 
 
Detection of Mutant Virus in Wild-type Virus Stocks 
The site-specific RT-PCR was designed to be more sensitive than Sanger 
sequencing and to provide another measure of confirmation of both the NAI assay and 
sequencing.  We needed to determine if our original stock of 182742WT virus had the 
E119V mutation at a low level or to discern if the 182742-MUT-E119V stock had a low 
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level of E119 present in the stock.  This was done through the optimization of the primers 
both by adjusting annealing temperature as well as adding the additional intentional 
mismatch at the 3′ end, in addition to the site specific mutation of the most 3′ base pair. 
We did not detect the E119V mutation in the 182742WT stock or the E119 in the 
182742-MUT-E119V stock (Figure 3.7).  Primer controls used to test the quality of RNA 
were the 2.1F and 2.3R as previously noted in our methods, and can be seen in lanes 4 
and 7 as positive controls for the 182742WT stocks.  There were no bands present in 
lanes 3 and 6 showing no detectable E119V in the WT stock.  There was also no band in 
lane 8 showing that the E119 is undetectable in the MUT stock. 
 
Figure 3.7. Site-specific RT-PCR with specific primers on 1% agarose gel stained with 
Ethidium bromide 
Lanes 
1 – 1kb plus DNA ladder 
2 – 182742WT with WT primers 
3 – 182742WT with MUT primers 
4 – 182742WT NA control 
5 – 182742WT (P2) with WT primers 
6 – 182742WT (P2) with MUT primers 
7 – 182742WT (P2) NA control 
8 – 182742-MUT with WT primers 
9 – 182742_MUT with MUT primers 
10 – 182742WT (picked plaque) with WT primers 
 
 1        2      3    4     5     6     7     8     9   10 
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Discussion 
Ducks are the primary reservoir host of all influenza A virus subtypes and thus are 
the source of all influenza A viruses that affect mammals, including humans.  This 
project was founded on the hypothesis that consumption by ducks of low levels of OC, 
similar to what has been reported to occur naturally, will promote selection of mutant 
viruses that are resistant to OC.  To test this hypothesis, we infected ducks with 2 
different LP H5N2 AIVs and attempted to detect OC-resistant virus in cloacal secretions.  
Detection of resistant viruses from swab samples was performed either by assaying 
individually plaque-picked virus for neuraminidase enzymatic activity in the presence of 
OC, followed by nucleotide sequencing, or by direct sequencing of virus from cloacal 
swab samples. 
We found that oseltamivir-resistant viruses arose on several occasions in mallard 
ducks that received water containing a low concentration of OC and that were infected 
with AIV.  Furthermore, those OC-resistant viruses rapidly came to be the dominant 
population of virus in treated ducks, likely the result of continued selective pressure. The 
day of detection of resistant virus was consistent with previous studies of children treated 
with oseltamivir during influenza virus infection, in which resistant strains were first 
detected on day 4 (Kiso et al, 2004) and on days 4 and 6 post treatment (Whitley et al, 
2001).  Resistant virus was not detected in control ducks that were not exposed to OC. 
Previous investigations indicate that a considerable amount of OC is not broken 
down during normal or chemical processes, which can lead to the buildup of OC in the 
environment.  Proposed calculations suggest that OC can remain in the environment for 
up to 18 days at levels of 0.08-0.23 μg/L (Singer et al, 2007, Bartels and von Tumpling jr 
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2008).  An indication of the highest predicted environmental concentration was proposed 
for Japan, a country which currently prescribes a large amount of oseltamivir, to be 0.028 
μg/L (Bartels and von Tumpling jr 2008). These are projected values, as different issues 
such as water size, prescribed amounts of oseltamivir, and the actual level of a pandemic 
would all play a role in environmental concentrations.  
Recently, actual levels of OC were measured in regional waters of Japan. Prior to 
the beginning of the 2007-2008 influenza season OC was not detected in the Yodo river 
system, but concentrations of 2-58 ng/L were detected during the influenza season 
(Söderström et al, 2009).  During the 2008-2009 influenza season, levels of OC rose to 
peak concentrations of 293.3 ng/L of OC in sewage treatment plant discharge with river 
water levels ranging from 6.6-190.2 ng/L (Ghosh et al, 2010). Both of these proposed and 
detected values guided our choice of concentrations of OC in our mallard studies.   
We analyzed the effects of AIV infection in mallards during consumption of OC 
contaminated water and concluded that drug induced resistant viruses can emerge.  This 
is concerning in that OC resistant viruses are already on the rise in humans (Sheu et al, 
2008, Dharan et al, 2009, Meijer et al, 2009, Hurt et al, 2009), even in areas of low 
oseltamivir drug use (Hauge et al, 2009).  Since waterfowl are the natural reservoir for all 
influenza virus subtypes, there is a need to understand all possible effects of mallards 
ingesting OC, and the outcomes in waterfowl with different AIV strains.   
Our PK studies indicated that ducks vary considerably from humans in their 
uptake and metabolism of OP and its metabolite OC.  Based on plasma levels, ducks 
appear to absorb OP adequately after oral gavage, but may convert OP to OC in the gut 
instead of trafficking through the liver.  This conclusion was based on low clearance and 
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short Tmax values.  This potential conversion in the gut may play a larger role when the 
duck is infected with LPAI, since replication occurs in the digestive tract.  Additional 
research to look at the actual concentrations of OC present in the duck digestive tract may 
better elucidate the actual interaction of drug and virus. 
Analyzing the replication kinetics of both viruses indicated that the E119V 
mutation from the 182742 mallard virus appears to have a selective advantage in the 
presence of OC, and has similar growth kinetics in MDCK cells compared to the wild-
type parental virus.  While we did not evaluate the HA gene in this study, the interactions 
of HA and NA interplay with compensations in the HA or differences in NA enzymatic 
activity may both be responsible for the increased plaque size relative to wild-type and 
warrants further evaluation (Kaverin et al, 1998, Mitnaul et al, 2000, Wagner et al, 2002, 
Gerloff et al, 2009, Rameix-Welti et al, 2008).  HA mutations can also lead to reduced 
ability of binding of virus to sialic acids that can lead to a reduced dependence of virus on 
functions provided by NA (Staschke et al, 1995, McKimm-Breschkin et al, 1996, 
Gubareva et al, 1996).  We were not able to assay NA activity accurately due to a loss of 
stock viruses due to a freezer failure. 
Within the neuraminidase gene there are 8 amino acids called catalytic residues 
(R-118, D-151, R-152, R-224, E-276, R-292, R-371, and Y-406) so named because they 
have direct contact with the substrate, and 11 framework residues (E-119, R-156, W-178, 
S-179, D-198, I-222, E-227, E-277, N-294, and E-425) which play a role in the 
stabilization of the active site (Coleman et al, 1983).  The E119V mutation has been 
detected in virus from patients treated with oseltamivir (Baz et al, 2006, Ison et al, 2006, 
Kiso et al, 2004, Okomo-Adhiambo et al, 2010) and in vitro and in vivo models have 
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shown that viruses with this mutation replicate and transmit as efficiently as its parent 
wild-type virus (Herlocher et al, 2004, Yen et al, 2005). 
We observed that mallards inoculated with the E119V mutant virus, alone or as a 
mixture with wild-type virus, failed to shed detectable quantities of the E119V virus or to 
transmit that virus to contact naive ducks.  Only the wild-type virus was transmitted in all 
three groups.  This observation suggests that that the neuraminidase mutation of E119V is 
not as stable within mallards as it is in cell culture.  While in vitro, the 182742-MUT-
E119V had similiar replication efficiencies and larger plaque sizes compared to wild-type 
virus, but, in vivo, the E119V mutation was not detected either through Sanger 
sequencing or site-specific RT-PCR following transmission from infected to contact 
ducks.  There is the possibility that this mutation was unstable upon infection, and that 
the 182742-MUT-E119V virus reverted to wild-type within the mallard host.  It is also 
the possible that the wild-type was present below the level of detection of our assays in 
the E119V resistant viral stock used to inoculate the mallards, or that the wild-type strain 
out-competed the E119V mutant virus within the mallard.  Indeed, because of the poor 
fidelity of the influenza virus RNA polymerase, it is likely that some very low level 
contamination of the wild-type and mutant stock viruses with each other was present 
simply because the viruses are essentially a quasispecies. 
While Sanger sequencing has been shown to be very accurate in detecting 
mutations, studies have shown that customized pyrosequencing is more sensitive in 
detecting very low levels of point mutations (Levine et al, 2011).  However, 
pyrosequencing is very expensive and was not conducted as part of these experiments.  
Other recent research has utilized quantitative real-time or real-time RT-PCR coupled 
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with mathematical models based on differences in Ct values between wild-type and 
resistant strains for comparison.  This can be extremely sensitive for detecting very low 
levels of a specific mutation (Chidlow et al, 2010, Hurt et al, 2010, Liu et al, 2010, 
Renaud et al, 2010, van der Vries et al, 2010).  While we did base our site-specific RT-
PCR on these models, which correlated with our Sanger sequencing results (Figure 3.8), 
we recognize that there is a different level of sensitivity in these methods.   
 
 




Figure 3.8. (A), site-specific RT-PCR on RNA isolated from cloacal swabs of duck 3 in 
experiment two on days 2-6 post inoculation using WT primers (B), site-specific RT-
PCR on the same RNA from fig A using MUT primers (C) chromatograms of DNA 
sequenced from same duck as in fig A and B on days 4-6 post inoculation showing the 







  We did not detect the E119 wild-type in the E119V mutant strain or the E119V 
mutant strain in the wild-type strain using either Sanger sequencing or site-specific RT-
PCR assays.  We also utilized both methods in the mallard transmission studies and did 
not detect the E119V mutation in cloacal swabs from any ducks in all 3 groups. While 
traditional ferret transmission studies look at aerosol or direct contact transmission once 
the animal is already shedding virus, we choose a different route for these mallard 
studies.  Since there is repeated and close interaction of mallards directly in the wild, we 
allowed this same close contact with the mallard ducks following inoculation of virus to 
time of interaction with contact naïve ducks.  This would be a more likely representation 
of what happens in nature and would include the possibility of either direct transmission 
or environmental contamination transmission.  More avian viruses with neuraminidase 
mutations should be tested in mallards both in the presence and absence of OC, to better 
evaluate the potential role this could play in nature. 
We have utilized a novel experimental procedure to evaluate the effects of LPAI 
in mallard ducks within an environment contaminated with OC.  As resistant viruses 
continue to emerge and evolve, we need to evaluate their ability to transmit and persist 
with or without selective pressure.  While ferrets are the acceptable model to evaluate 
oseltamivir-resistant strains that could affect humans, we need to consider the natural 
reservoir of influenza viruses and the likelihood that these viruses will survive in nature.  
The results of this study can now be used with other models to continue to understand the 
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